AU2013385618B2 - Multifunctional quinoline derivatives as anti-neurodegenerative agents - Google Patents
Multifunctional quinoline derivatives as anti-neurodegenerative agents Download PDFInfo
- Publication number
- AU2013385618B2 AU2013385618B2 AU2013385618A AU2013385618A AU2013385618B2 AU 2013385618 B2 AU2013385618 B2 AU 2013385618B2 AU 2013385618 A AU2013385618 A AU 2013385618A AU 2013385618 A AU2013385618 A AU 2013385618A AU 2013385618 B2 AU2013385618 B2 AU 2013385618B2
- Authority
- AU
- Australia
- Prior art keywords
- quinolin
- undecan
- methoxyquinolin
- chloro
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title description 9
- 230000002555 anti-neurodegenerative effect Effects 0.000 title description 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- -1 8-methoxyquinolin-2-yl Chemical group 0.000 claims description 205
- 229910052739 hydrogen Inorganic materials 0.000 claims description 102
- 239000001257 hydrogen Substances 0.000 claims description 101
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 92
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000002947 alkylene group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 14
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 125000005237 alkyleneamino group Chemical group 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 229910052736 halogen Chemical group 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 208000020431 spinal cord injury Diseases 0.000 claims description 8
- 230000007786 learning performance Effects 0.000 claims description 6
- 230000007334 memory performance Effects 0.000 claims description 6
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 6
- UDOHNFDNAFROLI-UHFFFAOYSA-N 2-(12-hydroxydodecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCCCO)=CC=C21 UDOHNFDNAFROLI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- QDFLURPUBPBKKM-UHFFFAOYSA-N 10-(8-ethoxyquinolin-2-yl)decan-1-ol Chemical compound C1=C(CCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 QDFLURPUBPBKKM-UHFFFAOYSA-N 0.000 claims description 4
- KNMDDAXPYDLLIX-UHFFFAOYSA-N 10-(8-methoxyquinolin-2-yl)decan-1-ol Chemical compound C1=C(CCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 KNMDDAXPYDLLIX-UHFFFAOYSA-N 0.000 claims description 4
- DTZCJXTYHRNEGW-UHFFFAOYSA-N 10-(8-propan-2-yloxyquinolin-2-yl)decan-1-ol Chemical compound C1=C(CCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 DTZCJXTYHRNEGW-UHFFFAOYSA-N 0.000 claims description 4
- FAXMCVQBQVXHPF-UHFFFAOYSA-N 10-[8-(cyclopropylmethoxy)quinolin-2-yl]decan-1-ol Chemical compound C12=NC(CCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 FAXMCVQBQVXHPF-UHFFFAOYSA-N 0.000 claims description 4
- YSTDGIZKOZZGCU-UHFFFAOYSA-N 11-(8-ethoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 YSTDGIZKOZZGCU-UHFFFAOYSA-N 0.000 claims description 4
- KKWIRVPVMYONCW-UHFFFAOYSA-N 11-(8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 KKWIRVPVMYONCW-UHFFFAOYSA-N 0.000 claims description 4
- LWVFCXGUYBPGHU-UHFFFAOYSA-N 11-(8-phenylmethoxyquinolin-2-yl)undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 LWVFCXGUYBPGHU-UHFFFAOYSA-N 0.000 claims description 4
- AOINQWHDIWBEEN-UHFFFAOYSA-N 11-[8-(cyclopropylmethoxy)quinolin-2-yl]undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 AOINQWHDIWBEEN-UHFFFAOYSA-N 0.000 claims description 4
- ZYDRTJDJYPYWBT-UHFFFAOYSA-N 12-(5-fluoro-8-methoxyquinolin-2-yl)dodecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCO)N=C2C(OC)=CC=C(F)C2=C1 ZYDRTJDJYPYWBT-UHFFFAOYSA-N 0.000 claims description 4
- ODDLWCKRDCIDET-UHFFFAOYSA-N 12-(8-ethoxyquinolin-2-yl)dodecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 ODDLWCKRDCIDET-UHFFFAOYSA-N 0.000 claims description 4
- FLWNUPKBCGISMZ-UHFFFAOYSA-N 12-(8-methoxyquinolin-2-yl)dodecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 FLWNUPKBCGISMZ-UHFFFAOYSA-N 0.000 claims description 4
- DENCELAFXAZVGU-UHFFFAOYSA-N 12-(8-phenylmethoxyquinolin-2-yl)dodecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 DENCELAFXAZVGU-UHFFFAOYSA-N 0.000 claims description 4
- KKQRUKSXDAHBOV-UHFFFAOYSA-N 12-(8-propan-2-yloxyquinolin-2-yl)dodecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 KKQRUKSXDAHBOV-UHFFFAOYSA-N 0.000 claims description 4
- CFRJBTGJWCIKCH-UHFFFAOYSA-N 12-[8-(cyclopropylmethoxy)quinolin-2-yl]dodecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 CFRJBTGJWCIKCH-UHFFFAOYSA-N 0.000 claims description 4
- GQPUZFPFJHPWMW-UHFFFAOYSA-N 13-(8-ethoxyquinolin-2-yl)tridecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 GQPUZFPFJHPWMW-UHFFFAOYSA-N 0.000 claims description 4
- YTJXLKZSEQIRGW-UHFFFAOYSA-N 13-(8-methoxyquinolin-2-yl)tridecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 YTJXLKZSEQIRGW-UHFFFAOYSA-N 0.000 claims description 4
- ZMKCKFHLLPDEOK-UHFFFAOYSA-N 13-(8-phenylmethoxyquinolin-2-yl)tridecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 ZMKCKFHLLPDEOK-UHFFFAOYSA-N 0.000 claims description 4
- LVSDZRSGUUCVIC-UHFFFAOYSA-N 13-(8-propan-2-yloxyquinolin-2-yl)tridecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 LVSDZRSGUUCVIC-UHFFFAOYSA-N 0.000 claims description 4
- BLHPNMZDUKSSQY-UHFFFAOYSA-N 13-[8-(cyclopropylmethoxy)quinolin-2-yl]tridecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 BLHPNMZDUKSSQY-UHFFFAOYSA-N 0.000 claims description 4
- LLJSVNZKSLXPLF-UHFFFAOYSA-N 15-(5-chloro-8-ethoxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OCC)=CC=C(Cl)C2=C1 LLJSVNZKSLXPLF-UHFFFAOYSA-N 0.000 claims description 4
- IGGQJLUPHZIQOL-UHFFFAOYSA-N 15-(5-chloro-8-methoxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 IGGQJLUPHZIQOL-UHFFFAOYSA-N 0.000 claims description 4
- SGZSPKGQRHIKGA-UHFFFAOYSA-N 15-(5-chloro-8-propan-2-yloxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OC(C)C)=CC=C(Cl)C2=C1 SGZSPKGQRHIKGA-UHFFFAOYSA-N 0.000 claims description 4
- UXUJMELDWXXMAK-UHFFFAOYSA-N 15-(8-ethoxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 UXUJMELDWXXMAK-UHFFFAOYSA-N 0.000 claims description 4
- XMZCSDLUWWDQGZ-UHFFFAOYSA-N 15-(8-methoxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 XMZCSDLUWWDQGZ-UHFFFAOYSA-N 0.000 claims description 4
- BLPVUTPKHXIBAB-UHFFFAOYSA-N 15-(8-phenylmethoxyquinolin-2-yl)pentadecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 BLPVUTPKHXIBAB-UHFFFAOYSA-N 0.000 claims description 4
- BTWKADFATGAUFF-UHFFFAOYSA-N 15-(8-propan-2-yloxyquinolin-2-yl)pentadecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 BTWKADFATGAUFF-UHFFFAOYSA-N 0.000 claims description 4
- NAWMIQVYUJPVNX-UHFFFAOYSA-N 15-[5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl]pentadecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCCCO)=CC=C2C(Cl)=CC=C1OCC1CC1 NAWMIQVYUJPVNX-UHFFFAOYSA-N 0.000 claims description 4
- PVNQJXVDGNWIOS-UHFFFAOYSA-N 15-[8-(cyclopropylmethoxy)quinolin-2-yl]pentadecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 PVNQJXVDGNWIOS-UHFFFAOYSA-N 0.000 claims description 4
- MLWSCUOIQMMIMB-UHFFFAOYSA-N 15-[8-(trifluoromethoxy)quinolin-2-yl]pentadecan-1-ol Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(CCCCCCCCCCCCCCCO)=CC=C21 MLWSCUOIQMMIMB-UHFFFAOYSA-N 0.000 claims description 4
- SQUZDHVARUTGDI-UHFFFAOYSA-N 2-(10-hydroxydecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCO)=CC=C21 SQUZDHVARUTGDI-UHFFFAOYSA-N 0.000 claims description 4
- ICABGJQHJWILJU-UHFFFAOYSA-N 2-(11-hydroxyundecyl)-6-methylquinolin-8-ol Chemical compound N1=C(CCCCCCCCCCCO)C=CC2=CC(C)=CC(O)=C21 ICABGJQHJWILJU-UHFFFAOYSA-N 0.000 claims description 4
- STMHKKZRLGXLBB-UHFFFAOYSA-N 2-(13-hydroxytridecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCCCCO)=CC=C21 STMHKKZRLGXLBB-UHFFFAOYSA-N 0.000 claims description 4
- MZNQJHPWEXDUKS-UHFFFAOYSA-N 2-(14-hydroxytetradecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCCCCCO)=CC=C21 MZNQJHPWEXDUKS-UHFFFAOYSA-N 0.000 claims description 4
- RWFYHGBBAIWBJG-UHFFFAOYSA-N 2-(15-hydroxypentadecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCCCCCCO)=CC=C21 RWFYHGBBAIWBJG-UHFFFAOYSA-N 0.000 claims description 4
- UYHOZWLAIXWGJB-UHFFFAOYSA-N 2-(9-hydroxynonyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCO)=CC=C21 UYHOZWLAIXWGJB-UHFFFAOYSA-N 0.000 claims description 4
- ZPLHDDVQGIGJFU-UHFFFAOYSA-N 2-[[methyl(prop-2-ynyl)amino]methyl]quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CN(CC#C)C)=CC=C21 ZPLHDDVQGIGJFU-UHFFFAOYSA-N 0.000 claims description 4
- MILNJOSZFKPNHB-UHFFFAOYSA-N 5-chloro-2-[[methyl(prop-2-ynyl)amino]methyl]quinolin-8-ol Chemical compound ClC1=CC=C(O)C2=NC(CN(CC#C)C)=CC=C21 MILNJOSZFKPNHB-UHFFFAOYSA-N 0.000 claims description 4
- JLKCPBKFMOIQCC-UHFFFAOYSA-N 8-[(5,7-dichloro-8-methoxyquinolin-2-yl)methylamino]octan-1-ol Chemical compound C1=C(CNCCCCCCCCO)N=C2C(OC)=C(Cl)C=C(Cl)C2=C1 JLKCPBKFMOIQCC-UHFFFAOYSA-N 0.000 claims description 4
- QYRXHQHLAYWYHF-UHFFFAOYSA-N 8-[(5-chloro-8-ethoxyquinolin-2-yl)methylamino]octan-1-ol Chemical compound C1=C(CNCCCCCCCCO)N=C2C(OCC)=CC=C(Cl)C2=C1 QYRXHQHLAYWYHF-UHFFFAOYSA-N 0.000 claims description 4
- SSDKTUPPHWPFLU-UHFFFAOYSA-N 8-[(5-chloro-8-methoxyquinolin-2-yl)methylamino]octan-1-ol Chemical compound C1=C(CNCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 SSDKTUPPHWPFLU-UHFFFAOYSA-N 0.000 claims description 4
- QGIACUJBGDEFAR-UHFFFAOYSA-N 8-[(5-chloro-8-propan-2-yloxyquinolin-2-yl)methylamino]octan-1-ol Chemical compound C1=C(CNCCCCCCCCO)N=C2C(OC(C)C)=CC=C(Cl)C2=C1 QGIACUJBGDEFAR-UHFFFAOYSA-N 0.000 claims description 4
- IIJXGVLOSDBBNC-UHFFFAOYSA-N 8-[[5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl]methylamino]octan-1-ol Chemical compound C12=NC(CNCCCCCCCCO)=CC=C2C(Cl)=CC(Cl)=C1OCC1CC1 IIJXGVLOSDBBNC-UHFFFAOYSA-N 0.000 claims description 4
- ZJTMLYSSVRFBLC-UHFFFAOYSA-N 9-(5-chloro-8-ethoxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OCC)=CC=C(Cl)C2=C1 ZJTMLYSSVRFBLC-UHFFFAOYSA-N 0.000 claims description 4
- HAWRUXIENLSPGP-UHFFFAOYSA-N 9-(5-chloro-8-methoxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 HAWRUXIENLSPGP-UHFFFAOYSA-N 0.000 claims description 4
- QFUIKQIJSDCCHP-UHFFFAOYSA-N 9-(5-chloro-8-propan-2-yloxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OC(C)C)=CC=C(Cl)C2=C1 QFUIKQIJSDCCHP-UHFFFAOYSA-N 0.000 claims description 4
- OBEKLCHOVQTKSE-UHFFFAOYSA-N 9-(8-ethoxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 OBEKLCHOVQTKSE-UHFFFAOYSA-N 0.000 claims description 4
- COMNRVSDHMEORZ-UHFFFAOYSA-N 9-(8-propan-2-yloxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 COMNRVSDHMEORZ-UHFFFAOYSA-N 0.000 claims description 4
- ZVLKJYDPKRKVST-UHFFFAOYSA-N 10-(5-chloro-8-methoxyquinolin-2-yl)decan-1-ol Chemical compound C1=C(CCCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 ZVLKJYDPKRKVST-UHFFFAOYSA-N 0.000 claims description 3
- HLTVVTVKMVKLBN-UHFFFAOYSA-N 10-(5-chloro-8-methoxyquinolin-2-yl)decyl acetate Chemical compound C1=C(CCCCCCCCCCOC(C)=O)N=C2C(OC)=CC=C(Cl)C2=C1 HLTVVTVKMVKLBN-UHFFFAOYSA-N 0.000 claims description 3
- IZXRCUJAVJTCGS-UHFFFAOYSA-N 10-(8-phenylmethoxyquinolin-2-yl)decan-1-ol Chemical compound C12=NC(CCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 IZXRCUJAVJTCGS-UHFFFAOYSA-N 0.000 claims description 3
- TYUAMFMDMBTOAX-UHFFFAOYSA-N 11-(5,7-dichloro-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=C(Cl)C=C(Cl)C2=C1 TYUAMFMDMBTOAX-UHFFFAOYSA-N 0.000 claims description 3
- HNEDCYJFLCCYGE-UHFFFAOYSA-N 11-(8-propan-2-yloxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 HNEDCYJFLCCYGE-UHFFFAOYSA-N 0.000 claims description 3
- LEGHYZZDTFCTGF-UHFFFAOYSA-N 12-(5-chloro-8-methoxyquinolin-2-yl)dodecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 LEGHYZZDTFCTGF-UHFFFAOYSA-N 0.000 claims description 3
- YTFOHGOUZMQNQR-UHFFFAOYSA-N 12-(5-chloro-8-methoxyquinolin-2-yl)dodecyl acetate Chemical compound C1=C(CCCCCCCCCCCCOC(C)=O)N=C2C(OC)=CC=C(Cl)C2=C1 YTFOHGOUZMQNQR-UHFFFAOYSA-N 0.000 claims description 3
- FSZNIVPFQMYDLC-UHFFFAOYSA-N 13-(5-chloro-8-methoxyquinolin-2-yl)tridecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 FSZNIVPFQMYDLC-UHFFFAOYSA-N 0.000 claims description 3
- HVWYZQCHBUGEOF-UHFFFAOYSA-N 13-(5-chloro-8-methoxyquinolin-2-yl)tridecyl acetate Chemical compound C1=C(CCCCCCCCCCCCCOC(C)=O)N=C2C(OC)=CC=C(Cl)C2=C1 HVWYZQCHBUGEOF-UHFFFAOYSA-N 0.000 claims description 3
- RPHITKCSUYXZMN-UHFFFAOYSA-N 9-(8-methoxyquinolin-2-yl)nonan-1-ol Chemical compound C1=C(CCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 RPHITKCSUYXZMN-UHFFFAOYSA-N 0.000 claims description 3
- RNHDLECTIGTEJH-UHFFFAOYSA-N 9-[5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl]nonan-1-ol Chemical compound C12=NC(CCCCCCCCCO)=CC=C2C(Cl)=CC=C1OCC1CC1 RNHDLECTIGTEJH-UHFFFAOYSA-N 0.000 claims description 3
- BDDPQDMXOKPTHO-UHFFFAOYSA-N 9-[8-(cyclopropylmethoxy)quinolin-2-yl]nonan-1-ol Chemical compound C12=NC(CCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 BDDPQDMXOKPTHO-UHFFFAOYSA-N 0.000 claims description 3
- DDPZFECNKXBAOO-UHFFFAOYSA-N 11-(6-chloro-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC(Cl)=CC2=C1 DDPZFECNKXBAOO-UHFFFAOYSA-N 0.000 claims description 2
- KQZYBQHNLMYCRH-UHFFFAOYSA-N 11-(7-fluoro-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=C(F)C=CC2=C1 KQZYBQHNLMYCRH-UHFFFAOYSA-N 0.000 claims description 2
- IILBBARQDQWEKG-UHFFFAOYSA-N 11-[8-(trifluoromethoxy)quinolin-2-yl]undecan-1-ol Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(CCCCCCCCCCCO)=CC=C21 IILBBARQDQWEKG-UHFFFAOYSA-N 0.000 claims description 2
- OBUKAZKTWXFBGL-UHFFFAOYSA-N 8-[[5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl]methylamino]octan-1-ol Chemical compound C12=NC(CNCCCCCCCCO)=CC=C2C(Cl)=CC=C1OCC1CC1 OBUKAZKTWXFBGL-UHFFFAOYSA-N 0.000 claims description 2
- CSPLMLBBGBYJLT-UHFFFAOYSA-N 9-(8-phenylmethoxyquinolin-2-yl)nonan-1-ol Chemical compound C12=NC(CCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 CSPLMLBBGBYJLT-UHFFFAOYSA-N 0.000 claims description 2
- POCDMHBRHRTRBX-UHFFFAOYSA-N 9-[8-(trifluoromethoxy)quinolin-2-yl]nonan-1-ol Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(CCCCCCCCCO)=CC=C21 POCDMHBRHRTRBX-UHFFFAOYSA-N 0.000 claims description 2
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 claims 14
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- YXJALKMWIRGPJL-UHFFFAOYSA-N 1-(8-ethoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=CC=C(OCC)C2=NC(C(O)CCCCCCCCCCCCC)=CC=C21 YXJALKMWIRGPJL-UHFFFAOYSA-N 0.000 claims 1
- MAJDLTMJJSMJDW-UHFFFAOYSA-N 1-(8-methoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=CC=C(OC)C2=NC(C(O)CCCCCCCCCCCCC)=CC=C21 MAJDLTMJJSMJDW-UHFFFAOYSA-N 0.000 claims 1
- OBFXOOHYJNBPOJ-UHFFFAOYSA-N 1-(8-phenylmethoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C12=NC(C(O)CCCCCCCCCCCCC)=CC=C2C=CC=C1OCC1=CC=CC=C1 OBFXOOHYJNBPOJ-UHFFFAOYSA-N 0.000 claims 1
- GXNAILIBEJYYDK-UHFFFAOYSA-N 1-(8-propan-2-yloxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=CC=C(OC(C)C)C2=NC(C(O)CCCCCCCCCCCCC)=CC=C21 GXNAILIBEJYYDK-UHFFFAOYSA-N 0.000 claims 1
- DOMZWPLXASPLCU-UHFFFAOYSA-N 1-[8-(cyclopropylmethoxy)quinolin-2-yl]tetradecan-1-ol Chemical compound C12=NC(C(O)CCCCCCCCCCCCC)=CC=C2C=CC=C1OCC1CC1 DOMZWPLXASPLCU-UHFFFAOYSA-N 0.000 claims 1
- PYTVNOURZJKWDX-UHFFFAOYSA-N 1-[8-(trifluoromethoxy)quinolin-2-yl]tetradecan-1-ol Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(C(O)CCCCCCCCCCCCC)=CC=C21 PYTVNOURZJKWDX-UHFFFAOYSA-N 0.000 claims 1
- IXVFETHYNWFHOK-UHFFFAOYSA-N 11-(5-chloro-8-phenylmethoxyquinolin-2-yl)undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(Cl)=CC=C1OCC1=CC=CC=C1 IXVFETHYNWFHOK-UHFFFAOYSA-N 0.000 claims 1
- FYQUGONYSHQSTJ-UHFFFAOYSA-N 11-(5-chloro-8-propan-2-yloxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC(C)C)=CC=C(Cl)C2=C1 FYQUGONYSHQSTJ-UHFFFAOYSA-N 0.000 claims 1
- CQBXYBQSALOEBB-UHFFFAOYSA-N 11-(5-fluoro-8-phenylmethoxyquinolin-2-yl)undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(F)=CC=C1OCC1=CC=CC=C1 CQBXYBQSALOEBB-UHFFFAOYSA-N 0.000 claims 1
- FTPKEEXWINXUCI-UHFFFAOYSA-N 11-(5-fluoro-8-propan-2-yloxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC(C)C)=CC=C(F)C2=C1 FTPKEEXWINXUCI-UHFFFAOYSA-N 0.000 claims 1
- COGPNFVLPBPPRA-UHFFFAOYSA-N 11-(5-methyl-8-propan-2-yloxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC(C)C)=CC=C(C)C2=C1 COGPNFVLPBPPRA-UHFFFAOYSA-N 0.000 claims 1
- RUYKCINGJGFMCL-UHFFFAOYSA-N 11-(6-chloro-5,8-dimethoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC(Cl)=C(OC)C2=C1 RUYKCINGJGFMCL-UHFFFAOYSA-N 0.000 claims 1
- HCJKYRSYCCJYME-UHFFFAOYSA-N 11-(6-fluoro-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC(F)=CC2=C1 HCJKYRSYCCJYME-UHFFFAOYSA-N 0.000 claims 1
- BUSXDPBVPUCIME-UHFFFAOYSA-N 11-[5-bromo-8-(cyclopropylmethoxy)quinolin-2-yl]undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(Br)=CC=C1OCC1CC1 BUSXDPBVPUCIME-UHFFFAOYSA-N 0.000 claims 1
- 239000005697 Dodecan-1-ol Substances 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 abstract description 11
- 239000000651 prodrug Substances 0.000 abstract description 11
- 230000004770 neurodegeneration Effects 0.000 abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 5
- 239000002207 metabolite Substances 0.000 abstract description 3
- 239000012453 solvate Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 150000007660 quinolones Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 101
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 125000000623 heterocyclic group Chemical group 0.000 description 24
- 239000000460 chlorine Substances 0.000 description 23
- 125000001072 heteroaryl group Chemical group 0.000 description 23
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 125000003342 alkenyl group Chemical group 0.000 description 14
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 101150041968 CDC13 gene Proteins 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 8
- 125000005233 alkylalcohol group Chemical group 0.000 description 8
- 125000001589 carboacyl group Chemical group 0.000 description 8
- 125000004181 carboxyalkyl group Chemical group 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 235000015320 potassium carbonate Nutrition 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 7
- 150000003248 quinolines Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- JCRQQQUHRPKCRV-UHFFFAOYSA-N 1-bromo-2-methylidenecyclopropane Chemical compound BrC1CC1=C JCRQQQUHRPKCRV-UHFFFAOYSA-N 0.000 description 5
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- JWSUYSBONRNZRW-UHFFFAOYSA-N 2,2-dimethyl-1h-quinoline Chemical compound C1=CC=C2C=CC(C)(C)NC2=C1 JWSUYSBONRNZRW-UHFFFAOYSA-N 0.000 description 4
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 4
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 102100023206 Neuromodulin Human genes 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 230000014511 neuron projection development Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- HVZFCSBJWIFSLN-UHFFFAOYSA-N 11-(5,7-dichloro-8-propan-2-yloxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC(C)C)=C(Cl)C=C(Cl)C2=C1 HVZFCSBJWIFSLN-UHFFFAOYSA-N 0.000 description 3
- YNMGACFVNUYLLK-UHFFFAOYSA-N 2-(11-hydroxyundecyl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(CCCCCCCCCCCO)=CC=C21 YNMGACFVNUYLLK-UHFFFAOYSA-N 0.000 description 3
- MEIGUAVTKQFSEF-UHFFFAOYSA-N 6-[bis[(8-methoxyquinolin-2-yl)methyl]amino]hexan-1-ol Chemical compound C1=CC=C(OC)C2=NC(CN(CCCCCCO)CC3=CC=C4C=CC=C(C4=N3)OC)=CC=C21 MEIGUAVTKQFSEF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- HUKWFGWAZGAAJT-UHFFFAOYSA-N n-[(5-chloro-8-ethoxyquinolin-2-yl)methyl]-n-methylprop-2-yn-1-amine Chemical compound C1=C(CN(C)CC#C)N=C2C(OCC)=CC=C(Cl)C2=C1 HUKWFGWAZGAAJT-UHFFFAOYSA-N 0.000 description 3
- SEPAMRRIXWTZCD-UHFFFAOYSA-N n-[(5-chloro-8-methoxyquinolin-2-yl)methyl]-n-methylprop-2-yn-1-amine Chemical compound C1=C(CN(C)CC#C)N=C2C(OC)=CC=C(Cl)C2=C1 SEPAMRRIXWTZCD-UHFFFAOYSA-N 0.000 description 3
- OUEGXKQVPRWNQM-UHFFFAOYSA-N n-[[5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl]methyl]-n-methylprop-2-yn-1-amine Chemical compound C12=NC(CN(CC#C)C)=CC=C2C(Cl)=CC=C1OCC1CC1 OUEGXKQVPRWNQM-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- ZVAGGISDAZTVCA-UHFFFAOYSA-N 11-(5,7-dichloro-8-ethoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OCC)=C(Cl)C=C(Cl)C2=C1 ZVAGGISDAZTVCA-UHFFFAOYSA-N 0.000 description 2
- IMNGNXYZKMGVQH-UHFFFAOYSA-N 11-(5,8-dimethoxyquinolin-2-yl)undecan-1-ol Chemical compound OCCCCCCCCCCCC1=CC=C2C(OC)=CC=C(OC)C2=N1 IMNGNXYZKMGVQH-UHFFFAOYSA-N 0.000 description 2
- ONEMUFBFMKNNQE-UHFFFAOYSA-N 11-(8-phenylmethoxyquinolin-4-yl)undecan-1-ol Chemical compound C1=CC=C2C(CCCCCCCCCCCO)=CC=NC2=C1OCC1=CC=CC=C1 ONEMUFBFMKNNQE-UHFFFAOYSA-N 0.000 description 2
- TWMYJYAVNZRURW-UHFFFAOYSA-N 11-[5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl]undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(Cl)=CC(Cl)=C1OCC1CC1 TWMYJYAVNZRURW-UHFFFAOYSA-N 0.000 description 2
- XKALOVKIVCNZQI-UHFFFAOYSA-N 12-(8-phenylmethoxyquinolin-4-yl)dodecan-1-ol Chemical compound C1=CC=C2C(CCCCCCCCCCCCO)=CC=NC2=C1OCC1=CC=CC=C1 XKALOVKIVCNZQI-UHFFFAOYSA-N 0.000 description 2
- WWWYYWWTZOTHDZ-UHFFFAOYSA-N 14-(8-ethoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCO)N=C2C(OCC)=CC=CC2=C1 WWWYYWWTZOTHDZ-UHFFFAOYSA-N 0.000 description 2
- SRYXHWPIRNFFTP-UHFFFAOYSA-N 14-(8-methoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCO)N=C2C(OC)=CC=CC2=C1 SRYXHWPIRNFFTP-UHFFFAOYSA-N 0.000 description 2
- VQYAZWABZPVMFF-UHFFFAOYSA-N 14-(8-phenylmethoxyquinolin-2-yl)tetradecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1=CC=CC=C1 VQYAZWABZPVMFF-UHFFFAOYSA-N 0.000 description 2
- UQFAWWOTKOWIQU-UHFFFAOYSA-N 14-(8-propan-2-yloxyquinolin-2-yl)tetradecan-1-ol Chemical compound C1=C(CCCCCCCCCCCCCCO)N=C2C(OC(C)C)=CC=CC2=C1 UQFAWWOTKOWIQU-UHFFFAOYSA-N 0.000 description 2
- RBNLVWCOJVEVAT-UHFFFAOYSA-N 14-[8-(cyclopropylmethoxy)quinolin-2-yl]tetradecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCCCCO)=CC=C2C=CC=C1OCC1CC1 RBNLVWCOJVEVAT-UHFFFAOYSA-N 0.000 description 2
- FIXDAPYSHIDNEL-UHFFFAOYSA-N 14-[8-(trifluoromethoxy)quinolin-2-yl]tetradecan-1-ol Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(CCCCCCCCCCCCCCO)=CC=C21 FIXDAPYSHIDNEL-UHFFFAOYSA-N 0.000 description 2
- VKPPLTILDLBDGI-UHFFFAOYSA-N 2-(11-hydroxyundecyl)-5-methylquinolin-8-ol Chemical compound OCCCCCCCCCCCC1=CC=C2C(C)=CC=C(O)C2=N1 VKPPLTILDLBDGI-UHFFFAOYSA-N 0.000 description 2
- FOWSXQSBWKFSMM-UHFFFAOYSA-N 2-[4-[(5,7-dichloro-8-methoxyquinolin-2-yl)methyl]piperazin-1-yl]ethanol Chemical compound N1=C2C(OC)=C(Cl)C=C(Cl)C2=CC=C1CN1CCN(CCO)CC1 FOWSXQSBWKFSMM-UHFFFAOYSA-N 0.000 description 2
- GECJWWMSEFXTMQ-UHFFFAOYSA-N 2-[4-[(5-chloro-8-ethoxyquinolin-2-yl)methyl]piperazin-1-yl]ethanol Chemical compound N1=C2C(OCC)=CC=C(Cl)C2=CC=C1CN1CCN(CCO)CC1 GECJWWMSEFXTMQ-UHFFFAOYSA-N 0.000 description 2
- UJLLAYHOBZXUGM-UHFFFAOYSA-N 2-[4-[(5-chloro-8-methoxyquinolin-2-yl)methyl]piperazin-1-yl]ethanol Chemical compound N1=C2C(OC)=CC=C(Cl)C2=CC=C1CN1CCN(CCO)CC1 UJLLAYHOBZXUGM-UHFFFAOYSA-N 0.000 description 2
- RRGWAQAFKRNJBS-UHFFFAOYSA-N 2-[4-[(5-chloro-8-propan-2-yloxyquinolin-2-yl)methyl]piperazin-1-yl]ethanol Chemical compound N1=C2C(OC(C)C)=CC=C(Cl)C2=CC=C1CN1CCN(CCO)CC1 RRGWAQAFKRNJBS-UHFFFAOYSA-N 0.000 description 2
- BYFCUXXJJAVLPI-UHFFFAOYSA-N 2-[4-[[5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl]methyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1CC1=CC=C(C(Cl)=CC(Cl)=C2OCC3CC3)C2=N1 BYFCUXXJJAVLPI-UHFFFAOYSA-N 0.000 description 2
- PZPKPRRSGFAFHY-UHFFFAOYSA-N 2-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol Chemical compound C1CN(CCO)CCN1CC1=CC=C(C=CC=C2O)C2=N1 PZPKPRRSGFAFHY-UHFFFAOYSA-N 0.000 description 2
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- YWQRGGFXAKGBBR-UHFFFAOYSA-N 4-(11-hydroxyundecyl)quinolin-8-ol Chemical compound C1=CC=C2C(CCCCCCCCCCCO)=CC=NC2=C1O YWQRGGFXAKGBBR-UHFFFAOYSA-N 0.000 description 2
- KMUSYIJAPSBYCV-UHFFFAOYSA-N 4-(12-hydroxydodecyl)quinolin-8-ol Chemical compound C1=CC=C2C(CCCCCCCCCCCCO)=CC=NC2=C1O KMUSYIJAPSBYCV-UHFFFAOYSA-N 0.000 description 2
- XJMQVFVLIPBSSV-UHFFFAOYSA-N 5-chloro-8-(cyclopropylmethoxy)-2-[(4-ethylpiperazin-1-yl)methyl]quinoline Chemical compound C1CN(CC)CCN1CC1=CC=C(C(Cl)=CC=C2OCC3CC3)C2=N1 XJMQVFVLIPBSSV-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003637 basic solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 2
- MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- WKGGMMSXXOTXOO-UHFFFAOYSA-N n-[(5,7-dichloro-8-methoxyquinolin-2-yl)methyl]-n-methylprop-2-yn-1-amine Chemical compound C1=C(CN(C)CC#C)N=C2C(OC)=C(Cl)C=C(Cl)C2=C1 WKGGMMSXXOTXOO-UHFFFAOYSA-N 0.000 description 2
- CIKNFBOEVURZKI-UHFFFAOYSA-N n-[(5-chloro-8-propan-2-yloxyquinolin-2-yl)methyl]-n-methylprop-2-yn-1-amine Chemical compound C1=C(CN(C)CC#C)N=C2C(OC(C)C)=CC=C(Cl)C2=C1 CIKNFBOEVURZKI-UHFFFAOYSA-N 0.000 description 2
- YRSYTQYMKICLQA-UHFFFAOYSA-N n-[[5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl]methyl]-n-methylprop-2-yn-1-amine Chemical compound C12=NC(CN(CC#C)C)=CC=C2C(Cl)=CC(Cl)=C1OCC1CC1 YRSYTQYMKICLQA-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 238000010825 rotarod performance test Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YKANSELGZBNNAH-UHFFFAOYSA-N undecan-1-ol Chemical compound [CH2]CCCCCCCCCCO YKANSELGZBNNAH-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- LGZMUUBPTDRQQM-UHFFFAOYSA-N 10-Bromo-1-decanol Chemical compound OCCCCCCCCCCBr LGZMUUBPTDRQQM-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- WNQKPJOOPFCOQV-UHFFFAOYSA-N 11-(5-bromo-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC=C(Br)C2=C1 WNQKPJOOPFCOQV-UHFFFAOYSA-N 0.000 description 1
- DUTUOHKWXVMGNH-UHFFFAOYSA-N 11-(5-chloro-8-methoxyquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC=C(Cl)C2=C1 DUTUOHKWXVMGNH-UHFFFAOYSA-N 0.000 description 1
- LZVSCMAMYLHWNG-UHFFFAOYSA-N 11-(5-methyl-8-phenylmethoxyquinolin-2-yl)undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(C)=CC=C1OCC1=CC=CC=C1 LZVSCMAMYLHWNG-UHFFFAOYSA-N 0.000 description 1
- DNVCFEZJAFKCHG-UHFFFAOYSA-N 11-(8-methoxy-5-methylquinolin-2-yl)undecan-1-ol Chemical compound C1=C(CCCCCCCCCCCO)N=C2C(OC)=CC=C(C)C2=C1 DNVCFEZJAFKCHG-UHFFFAOYSA-N 0.000 description 1
- AKTPETRXUNSGEU-UHFFFAOYSA-N 11-[8-(cyclopropylmethoxy)-5-fluoroquinolin-2-yl]undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(F)=CC=C1OCC1CC1 AKTPETRXUNSGEU-UHFFFAOYSA-N 0.000 description 1
- CJIPXNXLHWBBFJ-UHFFFAOYSA-N 11-[8-(cyclopropylmethoxy)-5-methylquinolin-2-yl]undecan-1-ol Chemical compound C12=NC(CCCCCCCCCCCO)=CC=C2C(C)=CC=C1OCC1CC1 CJIPXNXLHWBBFJ-UHFFFAOYSA-N 0.000 description 1
- XFGANBYCJWQYBI-UHFFFAOYSA-N 11-bromoundecan-1-ol Chemical compound OCCCCCCCCCCCBr XFGANBYCJWQYBI-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- ZFCOUBUSGHLCDT-UHFFFAOYSA-N 2-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC=C1OC(F)(F)F ZFCOUBUSGHLCDT-UHFFFAOYSA-N 0.000 description 1
- NBYLBWHHTUWMER-UHFFFAOYSA-N 2-Methylquinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(C)=CC=C21 NBYLBWHHTUWMER-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- IEOXPZFCARHDSX-UHFFFAOYSA-N 2-methyl-8-(trifluoromethoxy)quinoline Chemical compound C1=CC=C(OC(F)(F)F)C2=NC(C)=CC=C21 IEOXPZFCARHDSX-UHFFFAOYSA-N 0.000 description 1
- YFYYZKKXOAFQGS-UHFFFAOYSA-N 2-methyl-8-propan-2-yloxyquinoline Chemical compound C1=C(C)N=C2C(OC(C)C)=CC=CC2=C1 YFYYZKKXOAFQGS-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000004937 4H-carbazolyl group Chemical group C=1(C=CCC2=C3C=CC=CC3=NC12)* 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- KLVIQTJSVMYWGS-UHFFFAOYSA-N 5,7-dichloro-2-(11-hydroxyundecyl)quinolin-8-ol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CCCCCCCCCCCO)=CC=C21 KLVIQTJSVMYWGS-UHFFFAOYSA-N 0.000 description 1
- OAHVXRMKYQBQHP-UHFFFAOYSA-N 5-chloro-2-(11-hydroxyundecyl)quinolin-8-ol Chemical compound ClC1=CC=C(O)C2=NC(CCCCCCCCCCCO)=CC=C21 OAHVXRMKYQBQHP-UHFFFAOYSA-N 0.000 description 1
- JXLQDBFQVQYUSL-UHFFFAOYSA-N 5-chloro-8-(cyclopropylmethoxy)-2-methylquinoline Chemical compound C12=NC(C)=CC=C2C(Cl)=CC=C1OCC1CC1 JXLQDBFQVQYUSL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- IXYZTQJBAJFGKP-UHFFFAOYSA-N 8-ethoxy-2-methylquinoline Chemical compound C1=C(C)N=C2C(OCC)=CC=CC2=C1 IXYZTQJBAJFGKP-UHFFFAOYSA-N 0.000 description 1
- SLBPIHCMXPQAIQ-UHFFFAOYSA-N 8-hydroxyquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C(O)=CC=CC2=C1 SLBPIHCMXPQAIQ-UHFFFAOYSA-N 0.000 description 1
- OQXVXPBDSJQYRR-UHFFFAOYSA-N 8-methoxy-2-methylquinoline Chemical compound C1=C(C)N=C2C(OC)=CC=CC2=C1 OQXVXPBDSJQYRR-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000001413 spine osteoarthritis Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Abstract
Novel quinolone derivatives are disclosed. Also disclosed are synthesis and use thereof for treating neurodegenerative diseases. In an aspect, the invention relates to a composition comprising a therapeutically effective amount of the compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof and a pharmaceutically acceptable diluent or carrier. Further in another aspect, the invention relates to a composition comprising a compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof, and a pharmaceutically acceptable diluent or carrier tor use in treating a neurodegenerative disease. Yet in another aspect, the invention relates to a use of a compound as aforementioned in the manufacture of a medicament for treating a neurodegenerative disease. In one embodiment, the medicament is for treating.Alzheimer's disease.
Description
MULTIFUNCTIONAL QUINOLINE DERIVATIVES AS ANTINEURODEGENERATIVE AGENTS
BACKGROUND OF THE INVENTION US Patent Nos. 7,439,243 and 7,452,888 describe a series of quinoline derivatives useful for the treatment of CNS disorders, including Alzheimer’s disease. US Patent No. 7,009,053 describes a series of quinoline derivatives useful for treatment of Alzheimer's disease, Huntington's disease, Parkinson's disease, amylotrophic lateral sclerosis, stroke, ischemia, traumatic brain injury, spinal cord injury, and osteoarthritis.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
Formula (I) (I) wherein R1 is hydrogen, (Ci-Cs)alkyl, (Ci-C8)alkylene(C3-Cs)cycloalkyl, (Ci-Cs)haloalkyl, or (Ci-Cs)alkylene(C6-C2o)aryl; R2 is hydrogen or halogen; R3 is hydrogen, halogen, (Ci-Cs)alkyl, or (Ci-Cs)alkoxy; R4 is hydrogen, halogen, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, or (Ci-Cs)haloalkyl; R5 is hydrogen or (Ci-C2o)alkanol; R6 is hydrogen; and R7 is (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-C8)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-C8)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-C8)alkylene(8-methoxyquinolin-2-yl); or (II) wherein: R1, R2, R3, R4 and R6 are each as defined in (I) above; R5 is (C5-C2o)alkanol; and R7 is hydrogen, (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-C8)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-C8)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-C8)alkylene(8-methoxyquinolin-2-yl).In one embodiment, R2 is hydrogen;
In another embodiment, R1 is hydrogen, (Ci-Cs)alkyl, (Ci-C8)alkylene(C3-Cs)cycloalkyl, or (Ci-Cs)haloalkyl.
Described herein is a method for preparing the compound of the invention, the method comprising: (1) reacting the compound of Formula (II)
Formula (II) wherein: R2, R3, R4, R5, and R6 are each independently hydrogen; or R2, R4, R5, and R6 are each independently hydrogen and R3 is CH3; or R2, R3, R5, and R6 are each independently hydrogen and R4 is CH3, F, Cl, or Br; or R2, R5, R6 are each independently hydrogen, R3 is OCH3, and R4 is Cl; or R2, R4 is Cl and R3, R5, R6 are each independently hydrogen, with benzyl bromide, methyl iodide, ethyl iodide, 2-bromopropane, or methylenecyclopropyl bromide in a basic solution at about room temperature to about 80°C to obtain the compound of Formula (III)
Formula (III) wherein: R1 is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, or benzyl; and R2, R3, R4, R5, and R6 are each independently hydrogen; or R2, R4, R5, and R6 are each independently hydrogen and R3 is CH3; or R2, R3, R5, and R6 are each independently hydrogen and R4 is CH3, F, Cl, or Br; or R2, R5, R6 are each independently hydrogen, R3 is OCH3, and R4 is Cl; or R2, R4 is Cl and R3, R5, R6 are each independently hydrogen; (2) reacting the compound of Formula (III) with lithium bis(trimethylsilyl)amide and a bromo(CiC2o)alkanol in tetrahydrofuran at 0°C to obtain the compound of Formula (I)
Formula (I) wherein: R1 is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, or benzyl; R2, R3, R4, R5, and R6 are each independently hydrogen; or R2, R4, R5, and R6 are each independently hydrogen and R3 is CH3; or R2, R3, R5, and R6 are each independently hydrogen and R4 is CH3, F, Cl, or Br; or R2, R5, R6 are each independently hydrogen, R3 is OCH3, and R4 is Cl; or R3 is Cl, and R4 is OCH3 or R2, R4 is Cl and R3, R5, R6 are each independently hydrogen; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i3OH, (CH2)i50H, (3) reacting the compound of Formula (I), wherein R1 is benzyl, with hydrogen gas under pressure with palladium on carbon at room temperature in methanol or with boron trichloride in dichloromethane at 0°C to obtain the compound of Formula (I)
Formula (I) R1, R2, R3, R4, R5, and R6 are each independently hydrogen; or R1, R2, R4, R5, and R6 are each independently hydrogen and R3 is CH3; or R1, R2, R3, R5, and R6 are each independently hydrogen and R4 is CH3, F, Cl, or Br; or R1, R2, R5, R6 are each independently hydrogen, R3 is OCH3, and R4 is Cl; or R2, R4 is Cl and R1, R3, R5, R6 are each independently hydrogen; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i2OH, (CH2)i3OH, (CH2)i5OH; or (4) reacting the compound of Formula (I), wherein R1, R2, R3, R4, R5, and R6 are each independently hydrogen and R7 is (CH2)nOH, with N-chlorosuccinimide in methylene chloride at room temperature to afford the compound of Formula (I), wherein R1, R3, R5, and R6 are each independently hydrogen, R2 and R4 are each independently chlorine, and R7 is (CH2)nOH; or (5) reacting the compound of Formula (I), wherein R1 is methyl, R2, R3, R4, R5, and R6 are each independently hydrogen and R7 is (CH2)nOH, (CH2)i2OH or (CH2)i30H with concentrated hydrochloric acid, ICI3, and glacial acetic acid to afford the compound of Formula (I), wherein R1 is methyl, R2, R3, R5, and R6 are each independently hydrogen, R4 is Cl, and R7 is (CH2)i0OH, (CH2)hOH, (CH2)i2OH, (CH2)i3OH, (CH2)i5OH, (CH2)i0OCOCH3, (CH2)hOCOCH3, (CH2)i2OCOCH3, (CH2)i3OCOCH3; or (6) reacting 2-aminophenol with methylvinyl ketone in hydrochloric acid to obtain the compound of Formula (INT-1)
Formula (INT-1); (7) reacting the compound of Formula (INT-1) with methyl iodide, ethyl iodide, 2-bromopropane, methylenecyclopropyl bromide, or benzyl bromide in basic solution to afford the compound of Formula (III),
Formula (III) wherein R10 is methyl, ethyl, 2-propyl, methylenecyclopropyl, or benzyl; (8) reacting the compound of Formula (III), wherein R10 is methyl, ethyl, 2-propyl, methylenecyclopropyl, or benzyl, with lithium bis(trimethylsilyl)amide and 10-bromo-l-decanol or 11 -bromo-1 -undecanol in tetrahydrofuran at 0°C to obtain the compound of Formula (I), wherein R1 is methyl, ethyl, 2-propyl, methylenecyclopropyl, or benzyl; R2, R3, R4, R6, and R7 are each independently hydrogen; and R5 is (CH2)nOH or (CFk)i20Fl; (9) reacting the compound of Formula (I), wherein R1 is benzyl; R2, R3, R4, R6, and R7 are each independently hydrogen; and R5 is (CH2)nOH or (CFb)i20FI, with hydrogen gas under pressure with palladium on carbon at room temperature in methanol to obtain the compound of Formula (I), wherein R1 is hydrogen; R2, R3, R4, R6, and R7 are each independently hydrogen; and R5 is (CH2)nOH or (CFh)i20Fl; or (10) reacting 2-trifluoromethoxyanaline with crotonaldehyde to obtain 2-methyl-8-trifluormethoxyquinoline, which is treated with lithium bis(trimethylsilyl)amide and a bromo(CiC2o)alkanol in tetrahydrofuran at 0°C to obtain the compound of Formula (I), wherein R1 is trifluoroemethyl; R2, R3, R4, R5, and R7 are each independently hydrogen; and R7 is (CH2)ioOH, (CH2)hOH, (CH2)i2OH, (CH2)i30H, or (CH2)i50H; or (11) reacting an 8-hydroxy-2-methylquinoline compound of Formula (IV), wherein R1 is hydrogen, methyl, ethyl, 2-propyl, or methylenecyclopropyl,
Formula (V) with selenium dioxide in dioxane at elevated temperature to afford a compound of Formula (VI), R1 is hydrogen, methyl, ethyl, 2-propyl, or methylenecyclopropyl.
Formula (VI) (12) reacting the compound of Formula (VI), wherein R1 is hydrogen, methyl, ethyl, 2-propyl, or methylenecyclopropyl, with N-methylpropagylamine to obtain a compound of Formula (I), wherein R1 is hydrogen, CFF, CH2CH3, CFkCF[(CF[3)2, CFbCFI(CFl2)2, or CH(CH3)2, R2, R3, R4, R5, and R6 are each independently hydrogen; and R7 is CH2N(CH3)CH2OCH; or (13) reacting the compound of Formula (VI), R1 is hydrogen, methyl, ethyl, 2-propyl, or methylenecyclopropyl, with 2(piperazin-1-yl) ethanol to obtain a compound of Formula (I), wherein R1 is hydrogen, CH3, CH2CH3, CH2CH(CH3)2, CH2CH(CH2)2, or CH(CH3)2, R2, R3, R4, R5, and R6 are each independently hydrogen; and R7 is CH2(N(CH2CH2)2N)CH2CH20H; or (14) reacting compound of Formula (VI) with an amino(Ci-C2o)alkanol to obtain a compound of Formula (I), wherein R1 is hydrogen, CH3, CFhCFF, CFkCFl(CF[3)2, CH2CH(CH2)2, or CH(CH3)2; R2, R3, R4, R5, and R6 are each independently hydrogen; and R7 is CH2NH(CH2)sOH, or CH2N((CH2)60H)CH2(8-methoxyquinolin-2-yl). In another aspect, the invention relates to a composition comprising a a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
Further in another aspect, the invention relates to a method for the treatment of Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury, comprising administering to a subject in need thereof a therapeutically effective amount of the composition of the invention.
Also disclosed is use of a compound of the invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury.
Alternatively, the invention relates to a use of a compound of the invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury.
The invention is also related to a method for improving learning and/or memory performance in a patient of Alzheimer's disease, comprising administering a therapeutically effective amount of the composition of the invention to the patient with Alzheimer's disease. Alterantively, the invention relates to a compound of the invention or a pharmaceutically acceptable salt thereof, when used in improving learning and/or memory performance in a patient with Alzheimer’s disease.
Also disclosed is use of a compound of the invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for improving learning and/or memory performance in a patient with Alzheimer’s disease.
In the description in this specification reference may be made to subject matter which is not within the scope of the appended claims. That subject matter should be readily identified by a person skilled in the art and may assist in putting into practice the invention as defined in the appended claims.
These and other aspects will become apparent from the following description of the preferred embodiment taken in conjunction with the following drawings, although variations and modifications therein may be affected without departing from the spirit and scope of the novel concepts of the disclosure.
The accompanying drawings illustrate one or more embodiments of the invention and, together with the written description, serve to explain the principles of the invention. Wherever possible, the same reference numbers are used throughout the drawings to refer to the same or like elements of an embodiment.
BRIEF DESCRIPTION OF THE DRAWINGS FIGs. 1A-B show morphological analysis of the effects of compound C12 on ίΑβ formation and dissociation of fAps in the presence or absence of zinc ions. FIG. 2 shows compound C12 inhibiting polymerization of Αβ in the absence of zinc ions. FIGs. 3 A-B show compound C12 acting as a neuroprotective agent targeting ίΑβ. FIG. 4 shows quinoline derivatives-induced neurite outgrowth. FIG. 5 shows quinoline derivatives increased expression of GAP43 (a marker for neurite outgrowth). FIG. 6 shows the results of rotarod test. FIGs. 7A-D show the results of Morris water maze test. FIG. 8 shows an increase in GAP43 level and decrease in ίΑβ level in memory-deficit ίΑβ-lesioned mice after compound C12 treatment.
DETAILED DESCRIPTION OF THE INVENTION
The term “comprising” as used in this specification and claims means “consisting at least in part of’. When interpreting statements in this specification and claims which include “comprising”, other features besides the features prefaced by this term in each statement can also be present. Related terms such as “comprise” and “comprised” are to be interpreted in a similar manner.
The singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a moiety or substituent. For example, the moiety -CONFh is attached through the carbon atom.
The term “amino” refers to -NFh. The amino group can be optionally substituted as defined herein for the term “substituted.” The term “alkylamino” refers to -NR2, wherein at least one R is alkyl and the second R is alkyl or hydrogen. The term “acylamino” refers to N(R)C(=0)R, wherein each R is independently hydrogen, alkyl, or aryl.
The term “alkyl” refers to a Ci-Cis hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. Examples are methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-l-propyl (iso-butyl, -CH2CH(CH3)2), 2-butyl (sec-butyl, -CF^CFyCFbCFF), 2-methyl-2-propyl (tert-butyl, -C(CH3)3), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-l-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl. The alkyl can be a monovalent hydrocarbon radical, as described and exemplified above, or it can be a divalent hydrocarbon radical (i.e., alkylene). The alkyl can optionally be substituted with one or more alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulflnyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfmyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfmamoyl, sulflno, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxy. The alkyl can optionally be interrupted with one or more non-peroxide oxy (-0-), thio (-S-), amino (-N(H)-), methylene dioxy (-OCH2O-), carbonyl (-C(=0)-), carboxy (-0(=0)0-), carbonyldioxy (-00(=0)0-), carboxylato (-00(=0)-), imino (C=NH), sulfinyl (SO) or sulfonyl (SO2). Additionally, the alkyl can optionally be at least partially unsaturated, thereby providing an alkenyl.
The term “alkylene” refers to a saturated, branched or straight chain or cyclic hydrocarbon radical of 1-18 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to: methylene (-CH2-) 1,2-ethylene (-CH2CH2-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and the like. The alkylene can optionally be substituted with one or more alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulflnyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfmyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfmamoyl, sulflno, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl or hydroxy. Additionally, the alkylene can optionally be interrupted with one or more non-peroxide oxy (-0-), thio (-S-), amino (-N(H)-), methylene dioxy (-OCH2O-), carbonyl (-C(=0)-), carboxy (-0(=0)0-), carbonyldioxy (-00(=0)0-), carboxylato (-0C(=0)-), imine (C=NH), sulfinyl (SO) or sulfonyl (SO2). Moreover, the alkylene can optionally be at least partially unsaturated, thereby providing an alkenylene.
The term “alkynyl” refers to a monoradical branched or unbranched hydrocarbon chain, having a point of complete unsaturation (i.e., a carbon-carbon, sp triple bond). In one embodiment, the alkynyl group can have from 2 to 10 carbon atoms, or 2 to 6 carbon atoms. In another embodiment, the alkynyl group can have from 2 to 4 carbon atoms. This term is exemplified by groups such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1-octynyl, and the like. The alkynyl can be unsubstituted or substituted.
The term “alkoxy” refers to the group alkyl-Ο-, where alkyl is defined herein. Preferred alkoxy groups include, e.g., methoxy, ethoxy, n-propoxy, fvo-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like. The alkoxy can optionally be substituted with one or more halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfinyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfinamoyl, sulfino, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy.
The term “alkanol” refers to a compound of a general formula ROH, where R is alkyl, as defined herein.
The term “aryl” refers to an unsaturated aromatic carbocyclic group of from 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple condensed (fused) rings, wherein at least one ring is aromatic (e.g., naphthyl, dihydrophenanthrenyl, fluorenyl, or anthryl). Preferred aryls include phenyl, naphthyl and the like. The aryl can optionally be a divalent radical, thereby providing an arylene. The aryl can optionally be substituted with one or more alkyl, alkenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfinyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfmamoyl, sulflno, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy.
The terms “aryloxy” and “arylalkoxy” refer to, respectively, an aryl group bonded to an oxygen atom and an aralkyl group bonded to the oxygen atom at the alkyl moeity. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy.
The term “carbocycle” refers to a saturated, unsaturated or aromatic ring having 3 to 8 carbon atoms as a monocycle, 7 to 12 carbon atoms as a bicycle, and up to about 30 carbon atoms as a polycycle. Monocyclic carbocycles typically have 3 to 6 ring atoms, still more typically 5 or 6 ring atoms. Bicyclic carbocycles have 7 to 12 ring atoms, e.g., arranged as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, or 9 or 10 ring atoms arranged as a bicyclo [5,6] or [6,6] system. Examples of carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, l-cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, phenyl, spiryl and naphthyl. The carbocycle can be optionally substituted as described above for alkyl groups.
When a substituent is specified to be an atom or atoms of specified identity, “or a bond”, a configuration is referred to when the substituent is “a bond” that the groups that are immediately adjacent to the specified substituent are directly connected to each other by a chemically feasible bonding configuration.
The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like. The cycloalkyl can optionally be substituted with one or more alkyl, alkenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfinyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfmamoyl, sulfino, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy. The cycloalkyl can optionally be at least partially unsaturated, thereby providing a cycloalkenyl. Additionally, the cycloalkyl can optionally be a divalent radical, thereby providing a cycloalkylene.
The term “an effective amount” refers to an amount sufficient to effect beneficial or desired results. Determination of an effective amount for a given administration is well within the ordinary skill in the pharmaceutical arts.
The term “halo” refers to fluoro, chloro, bromo, and iodo. Similarly, the term “halogen” refers to fluorine, chlorine, bromine, and iodine.
The term “haloalkyl” refers to alkyl substituted by 1-4 halo groups, which may be the same or different. Representative haloalkyl groups include trifluoromethyl, 3-fluorododecyl, 12,12,12-trifluorododecyl, 2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.
The term “heteroaryl” is a monocyclic, bicyclic, or tricyclic ring system containing one, two, or three aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or substituted. The heteroaryl can optionally be a divalent radical, thereby providing a heteroarylene. Examples of heteroaryl groups include, but are not limited to, 2//-pyrrolyl, 3//-indolyl, 4//-quinolizinyl, 4H-carbazolyl, acridinyl, benzo[b]thienyl, benzothiazolyl, β-carbolinyl, carbazolyl, chromenyl, cinnaolinyl, dibenzo[b,d]furanyl, furazanyl, furyl, imidazolyl, imidizolyl, indazolyl, indolisinyl, indolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthyridinyl, naptho[2,3-b], oxazolyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, thiadiazolyl, thianthrenyl, thiazolyl, thienyl, triazolyl, and xanthenyl. In one embodiment the term “heteroaryl” denotes a monocyclic aromatic ring containing five or six ring atoms containing carbon and 1, 2, 3, or 4 heteroatoms independently selected from the group non-peroxide oxygen, sulfur, and N(Z) wherein Z is absent or is H, O, alkyl, phenyl, or benzyl. In another embodiment heteroaryl denotes an ortho-fused bicyclic heterocycle of about eight to ten ring atoms derived therefrom, particularly a benz-derivative or one derived by fusing a propylene, or tetramethylene diradical thereto.
The heteroaryl can optionally be substituted with one or more alkyl, alkenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfinyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfinamoyl, sulfino, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy.
The term “heterocycle” or “heterocyclyl” refers to a saturated or partially unsaturated ring system, containing at least one heteroatom selected from the group oxygen, nitrogen, and sulfur, and optionally substituted with alkyl, or C(=0)0Rb, wherein Rb is hydrogen or alkyl. Typically heterocycle is a monocyclic, bicyclic, or tricyclic group containing one or more heteroatoms selected from the group oxygen, nitrogen, and sulfur. A heterocycle group also can contain an oxo group (=0) attached to the ring. Non-limiting examples of heterocycle groups include 1,3-dihydrobenzofuran, 1,3-dioxolane, 1,4-dioxane, 1,4-dithiane, 2//-pyran, 2-pyrazoline, 4//-pyran, chromanyl, imidazolidinyl, imidazolinyl, indolinyl, isochromanyl, isoindolinyl, morpholine, piperazinyl, piperidine, piperidyl, pyrazolidine, pyrazolidinyl, pyrazolinyl, pyrrolidine, pyrroline, quinuclidine, and thiomorpholine. The heterocycle can optionally be a divalent radical, thereby providing a heterocyclene. The heterocycle can optionally be substituted with one or more alkyl, alkenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulflnyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulflnyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyannato, sulfamoyl, sulfmamoyl, sulfino, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy.
Examples of nitrogen heterocycles and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as N-alkoxy-nitrogen containing heterocycles.
The term “hydrate” refers to the complex where the solvent molecule is water.
The terms “individual,” “host,” “subject,” and “patient” are used interchangeably, and refer to a mammal, including, but not limited to, primates, including simians and humans.
The term “metabolite” refers to any compound of the Formula (I) produced in vivo or in vitro from the parent drug, or its prodrugs.
The pharmaceutically acceptable salts of the compounds described herein can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of many suitable salts are found in Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams & Wilkins, (2005).
Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form a compound of the Formula (I). Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
The prodrug can be readily prepared from the compounds of Formula (I) using methods known in the art. See, e.g. See Notari, R. E., “Theory and Practice of Prodrug Kinetics,” Methods in Enzymology, 112:309 323 (1985); Bodor, N., “Novel Approaches in Prodrug Design,” Drugs of the Future, 6(3):165 182 (1981); and Bundgaard, H., “Design of Prodrugs: Bioreversible-Derivatives for Various Functional Groups and Chemical Entities,” in Design of Prodrugs (H. Bundgaard, ed.), Elsevier, N.Y. (1985); Burger’s Medicinal Chemistry and Drug Chemistry,
Fifth Ed., Vol. 1, pp. 172 178, 949 982 (1995).
The term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula I, or a salt or physiologically functional derivative thereof) and a solvent. Such solvents, for the purpose of the invention, should not interfere with the biological activity of the solute. Non-limiting examples of suitable solvents include, but are not limited to water, methanol, ethanol, and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Non-limiting examples of suitable pharmaceutically acceptable solvents include water, ethanol, and acetic acid.
The phrase “room temperature” refers to a temperature in the range of about 20°C to about 30°C.
The term “substituted” is intended to indicate that one or more hydrogens on the atom indicated is replaced with a selection from the indicated group(s), provided that the indicated atom’s normal valency is not exceeded, and that the substitution results in a stable compound. Suitable indicated groups include, e.g., alkyl, alkenyl, alkylidenyl, alkenylidenyl, alkoxy, halo, haloalkyl, hydroxy, hydroxyalkyl, aryl, heteroaryl, heterocycle, cycloalkyl, alkanoyl, acyloxy, alkoxycarbonyl, amino, imino, alkylamino, acylamino, nitro, trifluoromethyl, trifluoromethoxy, carboxy, carboxyalkyl, keto, thioxo, alkylthio, alkylsulfinyl, alkylsulfonyl, cyano, acetamido, acetoxy, acetyl, benzamido, benzenesulfinyl, benzenesulfonamido, benzenesulfonyl, benzenesulfonylamino, benzoyl, benzoylamino, benzoyloxy, benzyl, benzyloxy, benzyloxycarbonyl, benzylthio, carbamoyl, carbamate, isocyanato, sulfamoyl, sulfinamoyl, sulfino, sulfo, sulfoamino, thiosulfo, NRxRy and/or COORx, wherein each Rx and Ry are independently H, alkyl, alkenyl, aryl, heteroaryl, heterocycle, cycloalkyl, or hydroxy. When a substituent is oxo (i.e., =0) or thioxo (i.e., =S) group, then two hydrogens on the atom are replaced.
The terms “treating” or “treat” or “treatment” refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse affect attributable to the disease.
The invention relates to multifunctional quinoline derivatives having following properties: metal chelation, clearance of reactive oxygen species, anti-aggregation, neurite outgrowth and neuron proliferation. They are useful for treating neurondegenerative disease involving neuronal toxicity or dysfunction induced by oxidative stress and other disorders associated with misfolding protein aggregation. In animal model, quinoline derivatives (B3 or Cl2) at 1 to 100 mg/kg, preferable 1 to 10 mg/kg, i.p. daily) were found to improve memory of micewithout causing significant toxicity.
In one aspect, the invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
Formula (I) (I) wherein R1 is hydrogen, (Ci-Cs)alkyl, (Ci-C8)alkylene(C3-Cs)cycloalkyl, (Ci-Cs)haloalkyl, or (Ci-Cs)alkylene(C6-C2o)aryl; R2 is hydrogen or halogen; R3 is hydrogen, halogen, (Ci-Cs)alkyl, or (Ci-Cs)alkoxy; R4 is hydrogen, halogen, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, or (Ci-Cs)haloalkyl; R5 is hydrogen or (Ci-C2o)alkanol; R6 is hydrogen; and R7 is (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-C8)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-Cs)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-C8)alkylene(8-methoxyquinolin-2-yl); or (II) wherein: R1, R2, R3, R4 and R6 are each as defined in (I) above; R5 is (C5-C2o)alkanol; and R7 is hydrogen, (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-C8)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-C8)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-Cs)alkylene(8-methoxyquinolin-2-yl).
In one embodiment of the invention, (A) wherein: R1 is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH2)2, CH2CH(CH3)2, CF3, or benzyl; R2 is hydrogen, F, or Cl; R3 is hydrogen, F, Cl, CH3, or OCH3; R4 is hydrogen, F, Cl, Br, CH3, OCH3, or CF3; R5 is hydrogen, (CH2)nOH, or (CH2)i20H; R6 is hydrogen; and R7 is hydrogen, (CH2)9OH, (CH2)ioOH, (CH2)nOH, (CH2)i20H, (CH2)i3OH, (CH2)i40H, (CH2)i5OH, (CH2)ioOCOCH3, (CH2)hOCOCH3, (CH2)i20C0CH3, (CH2)i3OCOCH3, CH2(N(CH2CH2)2N)CH2CH2OH, CH2N(CH3)CH2C=CH, CH2NH(CH2)80H, or CH2N((CH2)60H)CH2(8-methoxyquinolin-2-yl); or (B) wherein: R1, R2, R3, R4 and R6 are each as defined in (A) above; R5 is (CH2)nOH, or (CH2)i20H; and R7 is hydrogen, (CH2)9OH, (CH2)ioOH, (CH2)nOH, (CH2)i20H, (CH2)i3OH, (CH2)i4OH, (CH2)i5OH, (CH2)ioOCOCH3, (CH2)hOCOCH3, (CH2)i20C0CH3, (CH2)i3OCOCH3, CH2(N(CH2CH2)2N)CH2CH2OH, CH2N(CH3)CH2C=CH, CH2NH(CH2)80H, or CH2N((CH2)60H)CH2(8-methoxyquinolin-2-yl).
In another embodiment of the invention, wherein R1 is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH2CH(CH2)2, CF3, or benzyl; R2, R3, R4, R5, and R6 are each independently hydrogen; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i3OH, (CH2)i40H, (CH2)i50H, CH2(N(CH2CH2)2N)CH2CH2OH, or CH2N(CH3)CH2C=CH.
In another embodiment of the invention, wherein R1 is hydrogen, CH3, CH2CH3, CH2CH(CH3)2, CH2CH(CH2)2, or CH(CH3)2; R2, R3, R5, and R6 are each independently hydrogen; R4 is CH3, F, Cl, Br, CF3, or OCH3; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i3OH, (CH2)i50H, (CH2)ioOCOCH3, (CH2)iiOCOCH3, (CH2)i20C0CH3, (CH2)i3OCOCH3, CH2NH(CH2)80H, CH2(N(CH2CH2)2N)CH2CH2OH, or CH2N(CH3)CH2 C^CH.
In another embodiment of the invention, wherein R1 is hydrogen, CH3, CH2CH3, CH(CH2)2, or CH2CH(CH2)2; R2,R4 are each independently Cl; R3, R5, and R6 are each independently hydrogen; and R7 is (CH2)nOH, CH2NH(CH2)80H, or CH2N(CH3)CH2C=CH.
In another embodiment of the invention, wherein R1 is hydrogen, CH3, CH2CH3, CH2CH(CH3)2, CH2CH(CH2)2, CH(CH3)2, or benzyl; R2, R3, R4, R6, and R7 are each independently hydrogen; and R5 is (CH2)nOH or (CH2)i20H.
In another embodiment of the invention, wherein R1 is CH3; R2, R5, and R6 are each independently hydrogen; R3 and R4 are each independently OCH3 or Cl; and R7 is (CH2)nOH.
In another embodiment of the invention, the compound is selected from the group consisting of 9-(8-(benzyloxy)quinolin-2-yl)nonan-l-ol,10-(8-(benzyloxy)quinolin-2-yl)decan-l-ol, 11-(8-(benzyloxy)quinolin-2-yl)undecan-1 -ol, 12-(8-(benzyloxy)quinolin-2-yl)dodecan-1 -ol, 13-(8-(benzyloxy)quinolin-2-yl)tridecan-1 -ol, 14-((8-(benzyloxy)quinolin-2-yl)tetradecan-1 -ol, 15-(8-(benzyloxy)quinolin-2-yl)pentadecan-1 -ol, 11 -(8-(benzyloxy)-5-methylquinolin-2-yl)undecan-1 -ol, 1 l-(8-(benzyloxy)-6-methylquinolin-2-yl)undecan-l-ol, 1 l-(8-(benzyloxy)-5-fluoroquinolin-2-yl)undecan-l-ol, 1 l-(8-(benzyloxy)-5-chloroquinolin-2-yl)undecan-l-ol, 2-(9-hydroxynonyl)quinolin-8-ol, 2-(10-hydroxydecyl)quinolin-8-ol, 2-(11-hydroxyundecyl)quinolin-8-ol, 2-(12-hydroxydodecyl)quinolin-8-ol, 2-(13-hydroxytridecyl)quinolin-8-ol, 2-(14-hydroxytetradecyl)quinolin-8-ol, 2-(15-hydroxypentadecyl)quinolin-8-ol, 2-(1 l-hydroxyundecyl)-5-methylquinolin-8-ol, 2-(11-hydroxyundecyl)-6-methylquinolin-8-ol, 5-chloro-2-(l l-hydroxyundecyl)quinolin-8-ol, 9-(8-methoxyquinolin-2-yl)nonan-1-ol, 10-(8-methoxyquinolin-2-yl)decan-l-ol, 11-(8-methoxyquinolin-2-yl)undecan-1 -ol, 12-(8-methoxyquinolin-2-yl)dodecan-1 -ol, 13-(8-methoxyquinolin-2-yl)tridecan-1 -ol, 14-((8-methoxyquinolin-2-yl)tetradecan-1 -ol, 15-(8-methoxyquinolin-2-yl)pentadecan-1 -ol, 11 -(8-methoxy-5-methylquinolin-2-yl)undecan-1 -ol, 1 l-(5-fluoro-8-methoxyquinolin-2-yl)undecan-l-ol, 12-(5-fluoro-8-methoxyquinolin-2-yl)dodecan-l-ol, 9-(5-chloro-8-methoxyquinolin-2-yl)nonan-l-ol, 1 l-(5-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, 15-(5-chloro-8-methoxyquinolin-2-yl)pentadecan-l-ol, 11-(5-bromo-8-methoxyquinolin-2-yl)undecan-l-ol, 1 l-(8-methoxy-5-(trifluoromethyl)quinolin-2-yl)undecan-l-ol, 1 l-(5,8-dimethoxyquinolin-2-yl)undecan-l-ol, 1 l-(8-methoxy-6-methylquinolin-2-yl)undecan-l-ol, 1 l-(6-fluoro-8-methoxyquinolin-2-yl)undecan-l-ol, 11-(6-chloro-8-methoxyquinolin-2-yl)undecan-1 -ol, 11 -(7-fluoro-8-methoxyquinolin-2-yl)undecan-1 -ol, 1 l-(7-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, 1 l-(5-chloro-6,8-dimethoxyquinolin-2-yl)undecan-l-ol, 1 l-(6-chloro-5,8-dimethoxyquinolin-2-yl)undecan-l-ol, 1 l-(5,7-dichloro-8-methoxyquinolin-2-yl)undecan-1 -ol, 9-(8-ethoxyquinolin-2-yl)nonan-1 -ol, 10-(8-ethoxyquinolin-2-yl)decan-l-ol, 11 -(8-ethoxy quinolin-2-yl)undecan-1-ol, 12-(8-ethoxyquinolin-2-yl)dodecan-1 -ol, 13 -(8-ethoxyquinolin-2-yl)tridecan-1 -ol, 14-((8-ethoxyquinolin-2-yl)tetradecan-l-ol, 15-(8-ethoxyquinolin-2-yl)pentadecan-l-ol, 1 l-(8-ethoxy-5-methylquinolin-2-yl)undecan-l-ol, 1 l-(8-ethoxy-5-fluoroquinolin-2-yl)undecan-l-ol, 9-(5-chloro-8-ethoxyquinolin-2-yl)nonan-l-ol, 1 l-(5-chloro-8-ethoxyquinolin-2-yl)undecan-l-ol, 15-(5-chloro-8-ethoxyquinolin-2-yl)pentadecan-l-ol, 1 l-(5-bromo-8-ethoxyquinolin-2-yl)undecan-Ιοί, 1 l-(5,7-dichloro-8-ethoxyquinolin-2-yl)undecan-l-ol, 9-(8-isopropoxyquinolin-2-yl)nonan-1 -ol, 10-(8-isopropoxyquinolin-2-yl)decan-l-ol, 1 l-(8-isopropoxyquinolin-2-yl)undecan-l-ol, 12-(8-isopropoxyquinolin-2-yl)dodecan-l-ol, 13-(8-isopropoxyquinolin-2-yl)tridecan-l-ol, 14-((8-isopropoxyquinolin-2-yl)tetradecan-l-ol, 15-(8-isopropoxyquinolin-2-yl)pentadecan-l-ol, 1 l-(8-isopropoxy-5-methyl quinolin-2-yl)undecan-l-ol, 1 l-(5-fluoro-8-isopropoxyquinolin-2-yl)undecan-l-ol, 9-(5-chloro-8-isopropoxyquinolin-2-yl)nonan-l-ol, 1 l-(5-chloro-8-isopropoxyquinolin-2-yl)undecan-1 -ol, 15-(5-chloro-8-isopropoxyquinolin-2-yl)pentadecan-1 -ol, 1 l-(5-bromo-8-isopropoxyquinolin-2-yl)undecan-l-ol,, 11-(5,7-dichloro-8-isopropoxyquinolin-2-yl)undecan-1 -ol, 9-(8-(cyclopropylmethoxy)quinolin-2-yl)nonan-1 -ol, 10-(8-(cyclopropylmethoxy)quinolin-2-yl)decan-1 -ol, 11 -(8-(cyclopropylmethoxy)quinolin-2-yl)undecan-1 -ol, 12-(8-(cyclopropylmethoxy)quinolin-2-yl)dodecan-1 -ol, 13-(8-(cyclopropylmethoxy)quinolin-2-yl)tridecan-1 -ol, 14-((8-(cyclopropylmethoxy)quinolin-2-yl)tetradecan-l-ol, 15-(8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-l-ol, 11-(8-(cyclopropylmethoxy)-5-methylquinolin-2-yl)undecan-1 -ol, 11 -(8-(cyclopropylmethoxy)-5-fluoroquinolin-2-yl)undecan-l-ol, 9-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)nonan-Ιοί, 1 l-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol, 15-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-l-ol, 1 l-(5-bromo-8- (cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol, 1 l-(5,7-dichloro-8- (cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol, 5,7-dichloro-2-(l 1-hydro xyundecyl)quinolin- 8-ol, 10-(5-chloro-8-methoxyquinolin-2-yl)decan-l-ol, acetic acid 10-(5-chloro-8-methoxyquinolin-2-yl)decyl ester, 1 l-(5-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, acetic acid 1 l-(5-chloro-8-methoxyquinolin-2-yl)undecyl ester, 12-(5-chloro-8-methoxyquinolin-2-yl)dodecan-l-ol, acetic acid 12-(5-chloro-8-methoxyquinolin-2-yl)dodecyl ester, 13-(5-chloro- 8- methoxyquinolin-2-yl)tridecan-l-ol, acetic acid 13-(5-chloro-8-methoxyquinolin-2-yl)tridecyl ester, 1 l-(8-methoxyquinolin-4-(-yl)undecan-l-ol, 1 l-(8-ethoxyquinolin-4-(-yl)undecan-l-ol, 1 l-(8-isopropoxyquinolin-4-(-yl)undecan-l-ol, 1 l-(8-(cyclopropylmethoxy)quinolin-4-(-yl)undecan-l-ol, 1 l-(8-(benzyloxy)quinolin-4-(-yl)undecan-l-ol, 12-(8-(benzyloxy)quinolin-4-(-yl)dodecan-l-ol, 4-((1 l-hydroxyundecyl)quinolin-8-ol, 4-((12-hydroxydodecyl)quinolin-8-ol, 9- (8-(trifluoromethoxy)quinolin-2-yl)nonan-1 -ol, 11 -(8-(trifluoromethoxy)quinolin-2-yl)undecan-1 -ol, 14-((8-(trifluoromethoxy)quinolin-2-yl)tetradecan-1 -ol, 15-(8-(trifluoromethoxy)quinolin-2-yl)pentadecan-l-ol, 2-((4-((2-hydroxyethyl)piperazin-l-yl)methyl)quinolin-8-ol, 2-(4-(((5-chloro-8-methoxyquinolin-2-yl)methyl)piperazin-1 -yl)ethanol, 2-(4-(((5-chloro-8-ethoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5-chloro-8-isopropoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)piperazin-1 -yl)ethanol, 2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol, 5-chloro-2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol, N((5-chloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-1 -amine, N((5-chloro-8-ethoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-1 -amine, N((5-chloro-8-isopropoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-1 -amine, N((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, 8-((5-chloro-8-methoxyquinolin-2-yl)methylamino)octan-l-ol, 8-((5-chloro-8-ethoxyquinolin-2-yl)methylamino)octan-1 -ol, 8-((5-chloro-8-isopropoxyquinolin-2-yl)methylamino)octan-1 -ol, 8-((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-1 -ol, 8-((5,7-dichloro-8-methoxyquinolin-2-yl)methylamino)octan-1 -ol, 8-((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-1 -ol, and 6-(bis((8-methoxyquinolin-2-yl)methyl)amino)hexan-1 -ol.
In another aspect, the invention relates to a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier for use in treating a neurodegenerative disease, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer’s disease, brain traumatic injury, and spinal cord injury.
CHEMISTRY
Example 1 - Preparation of (8-benzyloxyquinolin-2-yl) and (8-hydroxyquinolin-2-yl)alkyl alcohol
R=H n= 9-15 A1-A7 R=5-CH3 n= 11 A8 R= H n= 9-15 B1-B7 R= 6-CH3 n= 11 A9 R=5-CH3 n=11 B8 R= 5-F n= 11 A10 (d) R= 6-CH3 n=11 B9 R= 5-CI n= 11 A11 -- R= 5-CI n= 11 B10
Reagents and conditions: (a) BnBr, KOH, EtOH, reflux, 15 h.; (b) 1) LHMDS, THF, 0 °C, 1 h.; 2) Br(CH2)„-iOH, rt, 16 - 36 h.; (c) H2, Pd/C, MeOH, rt, 6 to 10 h.; (d) BC13, CH2C12, 0 °C to rt, 3 h.
Method: The benzylation was performed as described by G. Serratrice et al. [Tetrahedron, 1996, 52, 4659-4672]. Benzyl bromide (6.45 g, 37.7 mmol) was added to a stirred solution of 2-methylquinaldine (5.0 g, 31.4 mmol) and KOH (1.95 g, 34.8 mmol) in 60 ml EtOH under reflux condition. After 15 h, the reaction mixture was filtered and filtrate removed in vacuo. The residue was purified by flash column chromatography with Hex/EA (6:1) and recrystallized in Hexane to give intermediate. LHMDS (2.2 to 2.5 equiv.) was treated with a stirred solution of (1 equiv.) in 20 ml THF at 0 °C for 1 h. Corresponding Br(CH2)n-iOH (1.0 to 1.2 equiv.) was added to a reaction mixture and the temperature was recovered to room temperature (RT) for further 15 to 36 h. The solvent was removed under a reduced pressure. The brown oily residue was purified by flash column chromatography with Hex/EA (3:1 to 2:1) or DCM/EA (15:1 to 9:1) and recrystallized by Hexane/EA to afford series of compounds A. Removal of benzyl group of series of compounds A was carried out in the presence of 10% Pd/C under hydrogen at RT for 610 h. The reaction mixture was filtered off and the filtrate purified by flash column chromatography by Hex/EA (4:1 to 3:1) to give series compound of B. To a stirred solution of All (0.65g, 1.4 mmol) in 20 ml CH2C12 was added 1M BCb (2.8 ml, 2.8 mmol) at an ice bath for 3 h. The reaction mixture was poured into an ice bath and extracted by 50 ml CH2C12. The organic layer was concentrated in vacuum and residue purified by flash column chromatography (EA) to afford the product (0.3 lg, 60%). 9-(8-(benzyloxy)quinolin-2-yl)nonan-l-ol (Al)
Yield (YD): 53%. *HNMR (400 MHz, ί/4-MeOD) 58.15 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 6.8 Hz, 2H), 7.31 ~ 7.41 (m, 5H), 7.29 (d, J= 2.0 Hz, 1H), 7.15 (dd, J= 7.6, 2.0 Hz, 1H), 5.40 (s, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 1.80 (quin, J= 6.8 Hz, 2H), 1.50 (t, J= 7.2 Hz, 2H), 1.28-1.42 (br, 11H); MS. m/z 400.0, [M+Na]+. 10- (8-(benzyloxy)quinolin-2-yl)decan-l-ol (A2) YD: 41%. 'HNMR (400 MHz, ί/4-MeOD) 58.14 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 7.6 Hz, 2H), 7.32- 7.42 (m, 5H), 7.28 (t, J= 12 Hz, 1H), 7.14 (dd, J= 7.6, 1.2 Hz, 1H), 5.38 (s, 2H), 3.51 (t, J = 6.8 Hz, 2H), 2.98 (t, J= 8.0 Hz, 2H), 1.79 (quin, J= 12 Hz, 2H), 1.49 (t, J= 6.8 Hz, 2H), 1.29-1.40 (br, 13H); MS. m/z 414.0, [M+Na]+. 11- (8-(benzyloxy)quinolin-2-yl)undecan-l-ol (A3) YD: 42%. lH NMR (400 MHz, CDCb) 58.02 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 12 Hz, 2H), 7.27 7.39 (m, 6H), 7.02 (d, J= 7.6 Hz, 1H), 5.46 (s, 2H), 3.63 (t, J= 6.8 Hz, 2H), 3.05 (t, J= 8 Hz, 2H), 1.84 (q, J= 7.6 Hz, 3H), 1.56 (t, J= 12 Hz, 2H), 1.29-1.46 (m, 12H); MS. m/z 428.3, [M+Na]+. 12- (8-(benzyloxy)quinolin-2-yl)dodecan-l-ol (A4) YD: 44%. lH NMR (400 MHz, ί/4-MeOD) 58.13 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 7.6 Hz, 2H), 7.31-7.40 (m, 5H), 7.26 (d, J=7.6Hz, 1H), 7.13 (dd, .7=7.6, 0.8 Hz, 1H), 5.37 (s, 2H), 3.51 (t,J = 6.8 Hz, 2H), 2.98 (t, J= 7.6 Hz, 2H), 1.78 (quin, J= 12 Hz, 2H), 1.49 (quin, J= 12 Hz, 2H), 1.25-1.41 (m, 17H); MS. m/z 442.3, [M+Na]+. 13- (8-(benzyloxy)quinolin-2-yl)tridecan-l-ol (A5) YD: 40%.¾ NMR (400 MHz, CDCb) 57.95 (d, J= 8.4 Hz, 1H), 7.45 (d, J= 7.6 Hz, 2H), 7.19 7.30 (m, 5H), 6.93 (d, J= 7.6 Hz, 1H), 5.40 (s, 2H), 3.55 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 7.6 Hz, 2H), 1.77 (quin, J= 7.6 Hz, 2H), 1.46 (t, J= 6.8 Hz, 2H), 1.19-1.38 (br, 19H); MS. m/z 456.3, [M+Na]+. 14- (8-(benzyloxy)quinolin-2-yl)tetradecan-l-ol (A6) YD: 51%. 'HNMR (400 MHz, ί/4-MeOD) 58.14 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 12 Hz, 2H), 7.33- 7.42 (m, 5H), 7.28 (t, J= 12 Hz, 1H), 7.14 (d, J= 6.8 Hz, 1H), 5.38 (s, 2H), 3.52 (t, J= 6.4 Hz, 2H), 2.98 (t, J= 8.0 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.47 (t, J= 6.8 Hz, 2H), 1.22-1.41 (br, 21H); MS. m/z 447.3, [M+H]+. 15- (8-(benzyloxy)quinolin-2-yl)pentadecan-l-ol (A7) YD: 42%. lH NMR (400 MHz, ί/4-MeOD) 58.15 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 12 Hz, 2H), 7.35-7.43 (m, 5H), 7.28-7.33 (m, 1H), 7.15 (dd, J= 7.6, 1.6 Hz, 1H), 5.39 (s, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 8.0 Hz, 2H), 1.79 (quin, J= 6.8 Hz, 2H), 1.51 (quin, J= 6.8 Hz, 2H), 1.221.41 (br, 23H); MS. m/z 462.3, [M+H]+. ll-(8-(benzyloxy)-5-methylquinolin-2-yl)undecan-l-ol (A8) YD: 47%. lH NMR (400 MHz, ί/4-MeOD) 58.30 (d, J= 8.4 Hz, 1H), 7.52 (d, J= 12 Hz, 2H), 7.44 (d, J= 8.8 Hz, 1H), 7.26-7.36 (m, 3H), 7.17 (d, J= 8.0 Hz, 2H), 7.02 (d, J= 8.0 Hz, 2H), 5.36 (s, 2H), 3.52 (t, J= 6.4 Hz, 2H), 3.00 (t, J= 7.6 Hz, 2H), 2.55 (s, 3H), 1.80 (quin, J= 7.2 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.28-1.41 (m, 15H); MS. m/z 420.3, [M+H]+. ll-(8-(benzyloxy)-6-methylquinolin-2-yl)undecan-l-ol (A9) YD: 40%. l¥i NMR (400 MHz, ί/4-MeOD) 58.03 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 7.2 Hz, 2H), 7.33-7.37 (m, 3H), 7.:26-7.30 (m, 1H), 7.16 (s, 1H), 7.00 (d, J= 1.2 Hz, 2H), 5.36 (s, 2H), 3.51 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 7.6 Hz, 2H), 2.40 (s, 3H), 1.76 (q, J= 7.6 Hz, 2H), 1.56 (t, J= 12 Hz, 2H), 1.29-1.46 (m, 15H); MS. m/z 442.3, [M+Na]+. ll-(8-(benzyloxy)-5-fhioroquinolin-2-yl)undecan-l-ol (A10) YD: 43%. Ή NMR (400 MHz, CDCb) 58.28 (d, J= 8.8 Hz, 1H), 7.51 (d, J= 7.2 Hz, 2H), 7.33 7.40 (m, 3H), 7.28 (t, J= 8.0 Hz, 1H), 6.89 ~ 6.98 (m, 2H), 5.42 (s, 2H), 3.61 (t, J= 6.4 Hz, 2H), 3.07 (t, J= 8 Hz, 2H), 1.83 (q, J= 7.6 Hz, 2H), 1.51-1.54 (m, 2H), 1.21-1.45 (m, 15H); MS. m/z 446.2, [M+Na]+. ll-(8-(benzyloxy)-5-chloroquinolin-2-yl)undecan-l-ol (All) YD: 43%. H NMR (400 MHz, ί/4-MeOD) 58.48 (d, J= 8.8 Hz, 1H), 7.52-7.57 (m, 3H), 7.46 (d, J= 8.4 Hz, 1H), 7.35 -7.39 (m, 2H), 7.31 (d, ./= 7.2 Hz, 1H), 7.14 (d,J= 8.4 Hz, 1H), 5.40 (s, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.03 (t, J= 7.6 Hz, 2H), 1.81 (quin, J= 7.2 Hz, 2H), 1.49 (t, J= 6.8 Hz, 2H), 1.28-1.41 (m, 15H); MS. m/z 462.2, [M+Na]+. 2-(9-hydroxynonyl)quinolin-8-ol (Bl) YD: 85%. l¥i NMR (400 MHz, ί/4-MeOD) 57.86 (d, J= 8.4 Hz, 1H), 7.22 (t, J= 7.6 Hz, 1H), 7.03-7.13 (m, 3H), 3.50 (t, J= 6.8 Hz, 2H), 2.75 (t, J= 8.0 Hz, 2H), 1.58 (quin, J= 6.8 Hz, 2H), 1.44 (quin, J= 6.8 Hz, 2H), 1.10-1.20 (m, 11H); HRMS (ESI): Calcd for [CisHisNCb-Naf: 310.1778, Found: 310.1779. 2-(10-hydroxydecyl)quinolin-8-ol (B2) YD: 85%. Ή NMR (400 MHz, CDCb) 58.01 (d, J= 8.4 Hz, 1H), 7.35 (t, J= 6.8 Hz, 1H), 7.26 7.28 (m, 2H), 7.11 (d, J = 7.2 Hz, 1H), 3.60 (t, J= 6.4 Hz, 2H), 2.92 (t, J= 7.6 Hz, 2H), 1.79 (quin, J= 6.8 Hz, 2H), 1.53 (quin, J= 6.8 Hz, 2H), 1.27-1.33 (br, 14H); MS. m/z 302.2, [M+H]+. 2-(ll-hydroxyundecyl)quinolin-8-ol (B3) YD: 77%. Ή NMR (400 MHz, CDCb) 58.04 (d, J= 8.4 Hz, 1H), 7.38 (t, J= 7.8 Hz, 1H), 7.27 7.31 (m, 2H), 7.14 (dd, J = 1.2, 7.6 Hz, 1H), 3.64 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 7.8 Hz, 2H), 1.83 (quin, J= 7.8 Hz, 2H), 1.55 (m, 2H), 1.28-1.36 (br, 17H); 1 MS. m/z 316.2, [M+H]+. 2-(12-hydroxydodecyl)quinolin-8-ol (B4) YD: 76%. Ή NMR (400 MHz, CDCb) 58.03 (d, J= 8.4 Hz, 1H), 7.36 (t, J= 8 Hz, 1H), 7.25 7.30 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 3.62 (t, J= 6.4 Hz, 2H), 2.94 (t, J= 7.6 Hz, 2H), 1.81 (quin, J= 7.6 Hz, 2H), 1.54 (quin, J= 6.8 Hz, 2H), 1.29-1.38 (br, 18H); MS. m/z 330.3, [M+H]+. 2-(13-hydroxytridecyl)quinolin-8-ol (B5) YD: 84%. l¥i NMR (400 MHz, CDC13) 58.03 (d, J= 8.4 Hz, 1H), 7.36 (t, J= 7.6 Hz, 1H), 7.26 7.30 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 3.62 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 7.6 Hz, 2H), 1.81 (quin, J= 7.2 Hz, 2H), 1.54 (quin, J= 6.8 Hz, 2H), 1.25-1.34 (br, 20H); MS. m/z 344.3, [M+H]+. 2-(14-hydroxytetradecyl)quinolin-8-ol (B6) YD: 87%. Ή NMR (400 MHz, CDCI3) 58.02 (d, J= 8.8 Hz, 1H), 7.36 (t, J= 7.6 Hz, 1H), 7.25 7.29 (m, 2H), 7.12 (d, J = 7.2 Hz, 1H), 3.61 (t, J= 6.4 Hz, 2H), 2.94 (t, J= 7.6 Hz, 2H), 1.80 (quin, J= 7.2 Hz, 2H), 1.54 (quin, J= 6.8 Hz, 2H), 1.24-1.34 (br, 24H); MS. m/z 358.3, [M+H]+. 2-(15-hydroxypentadecyl)quinolin-8-ol (B7) YD: 83%. 'HNMR (400 MHz, CDCI3) 58.04 (d, J= 8.4 Hz, 1H), 7.35 (t, J= 7.6 Hz, 1H), 7.26 7.29 (m, 2H), 7.13 (d, J = 7.2 Hz, 1H), 3.62 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 7.6 Hz, 2H), 1.80 (quin, J= 7.2 Hz, 2H), 1.54 (quin, J= 7.2 Hz, 2H), 1.24-1.37 (br, 24H); MS. m/z 372.3, [M+H]+. 2-(ll-hydroxyundecyl)-5-methylquinolin-8-ol (B8) YD: 83%. Ή NMR (400 MHz, ί/4-MeOD) 58.26 (d, J= 8.4 Hz, 1H), 7.39 (d, J= 8.8 Hz, 1H), 7.15 (d, J= 12 Hz, 1H), 6.93 (d, J= 3.2 Hz, 1H), 3.52 (t, J= 6.4 Hz, 2H), 2.95 (t, J= 8.0 Hz, 2H), 2.53 (s, 3H), 1.81 (quin, J= 12 Hz, 2H), 1.48 (quin, J= 6.8 Hz, 2H), 1.13-1.37 (m, 15H); MS. m/z 330.3, [M+H]+. 2-(ll-hydroxyundecyl)-6-methylquinolin-8-ol (B9) YD: 83%. l¥i NMR (400 MHz, ί/4-MeOD) 57.99 (d, J= 8.4 Hz, 1H), 7.29 (d, J= 8.8 Hz, 1H), 7.06 (s, 1H), 6.91 (s, 1H), 3.51 (t, J= 6.4 Hz, 2H), 2.90 (t, J= 8.0 Hz, 2H), 2.41 (s, 3H), 1.77 (quin, J= 6.4 Hz, 2H), 1.49 (quin, J= 6.8 Hz, 2H), 1.25-1.37 (m, 19H); MS. m/z 352.2, [M+Na]+. 5-chloro-2-(ll-hydroxyundecyl)quinolin-8-ol (BIO) 'HNMR (400 MHz, ί/4-MeOD) 58.39 (d, J= 8.8 Hz, 1H), 7.49 (d, J= 8.8 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 3.51 (t, J = 6.4 Hz, 2H), 2.98 (t, J= 8.0 Hz, 2H), 1.81 (quin, J= 12 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.27-1.35 (m, 15H); MS. m/z 350.2, [M+H]+. Example 2 - Preparation of (8-methoxyquinol-2-yl)alkyl alcohols
Reagents and conditions: (a) Mel, K2CO3, acetone, r.t, 10 h.; (b) 1) LHMDS, THF, 0 °C, 1 h.; 2) Br(CH2)„-iOH, rt, 12 - 30 h.
Method: Methyl iodide (10.8 g, 76.3 mmol) was added to a stirred solution of 2-methylquinaldine (1.0 g, 6.3 mmol) and K2CO3 (5.0 g, 36.2 mmol) in 30 ml acetone at RT for 10 h. The reaction mixture was filtered and filtrate removed under a reduced pressure. The residue was purified by flash column chromatography with Hex/EA (3:1) and recrystallized with Hexane/EA to give 8-methoxy-2-methylquinoline as intermediates. LHMDS (2.2 to 2.5 equiv.) was treated with a stirred solution of intermediate (1 equiv.) in THF at 0 °C for 1 h. Corresponding Br(CH2)n-iOH (1.0 to 1.2 equiv.) was added to a reaction mixture and recover to RT for further 12 to 30 h. The solvent was removed under a reduced pressure. The brown oily residue was purified by flash column chromatography with Hex/EA or DCM/EA and recrystallized by Hex/EA to afford series of compounds C. 9- (8-methoxyquinolin-2-yl)nonan-l-ol (Cl) YD: 50%. l¥i NMR (400 MHz, CDCb) 58.05 (d, J= 8.4 Hz, 1H), 7.33-7.42 (m, 3H), 7.04 (d, J = 6.8 Hz, 1H), 4.08 (s, 3H), 3.62 (t, J= 6.4 Hz, 2H), 3.07 (t, J= 7.6 Hz, 2H), 1.79 (br, 2H), 1.53 (br, 2H), 1.30-1.42 (br, 11H); MS. m/z 324.0, [M+Na]+. 10- (8-methoxyquinolin-2-yl)decan-l-ol (C2) YD: 38%. l¥i NMR (400 MHz, CDCb) 5 8.01 (d, J= 8.4 Hz, 1H), 7.36 (t, J= 7.6 Hz, 1H), 7.307.33 (m, 2H), 7.00 (d, J = 7.6 Hz, 1H), 4.05 (s, 3H), 3.60 (t, J= 6.8 Hz, 2H), 3.01 (t, J= 7.6 Hz, 2H), 1.79 (quin, J= 8 Hz, 2H), 1.52 (quin, J= 6.8 Hz, 2H), 1.30-1.43 (br, 12H); MS. m/z 316.2, [M+H]+. 11- (8-methoxyquinolin-2-yl)undecan-l-ol (C3) YD: 42%. Ή NMR (400 MHz, CDCb) 58.02 (d, J= 8.8 Hz, 1H), 7.38 (t, J= 7.8 Hz, 1H), 7.317.34 (m, 2H), 7.15 (d, J = 7.2 Hz, 1H), 4.06 (s, 3H), 3.61 (t, J= 6.8 Hz, 2H), 3.02 (t, J= 7.8 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.54 (quin, J= 6.8 Hz, 2H), 1.31-1.42 (br, 15H); MS. m/z 352.2, [M+Na]+. 12- (8-methoxyquinolin-2-yl)dodecan-l-ol (C4) YD: 38%. Ή NMR (400 MHz, CDCb) 58.01 (d, J= 8.8 Hz, 1H), 7.35 (t, J= 7.6 Hz, 1H), 7.30 7.32 (m, 2H), 7.01 (d, J = 7.2 Hz, 1H), 4.05 (s, 3H), 3.61 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 8 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.36-1.41 (m, 2H), 1.24-1.33 (br, 16H); MS. m/z 344.3, [M+H]+. 13- (8-methoxyquinolin-2-yl)tridecan-l-ol (C5) YD: 38%. Ή NMR (400 MHz, CDCb) 58.01 (d, J= 8.4 Hz, 1H), 7.37 (t, J= 7.6 Hz, 1H), 7.30 7.33 (m, 2H), 7.01 (d, J = 7.6 Hz, 1H), 4.05 (s, 3H), 3.61 (t, J= 12 Hz, 2H), 3.01 (t, J= 8 Hz, 2H), 1.80 (quin, J= 7.6 Hz, 2H), 1.54 (quin, J= 6.8 Hz , 2H), 1.36-1.43 (br, 19H); MS. m/z 358.3, [M+H]+. 14- (8-methoxyquinolin-2-yl)tetradecan-l-ol (C6) YD: 38%. Ή NMR (400 MHz, CDCb) 58.02 (d, J= 8.4 Hz, 1H), 7.31-7.38 (m, 3H), 7.01 (d, J = 7.2 Hz, 1H), 4.06 (s, 3H), 3.61 (t, J= 6.8 Hz, 2H), 3.02 (t, J= 8 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.54 (quin, J= 6.8 Hz , 2H), 1.23-1.40 (br, 21H); MS. m/z 394.3, [M+Na]+. 15-(8-methoxyquinolin-2-yl)pentadecan-l-ol (C7) YD: 31%. !H NMR (400 MHz, CDC13) 58.01 (d, ./= 8.4 Hz, 1H), 7.31-7.39 (m, 3H), 7.01 (d, J = 7.2 Hz, 1H), 4.06 (s, 3H), 3.63 (t, J= 6.8 Hz, 2H), 3.02 (t, J= 8 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.54 (quin, J= 6.8 Hz , 2H), 1.32-1.43 (br, 23H); MS. m/z 408.3, [M+H]+. ll-(8-methoxy-5-methylquinolin-2-yl)undecan-l-ol (C8) YD: 30%. l¥i NMR (400 MHz, ί/4-MeOD) 58.29 (d, J= 8.4 Hz, 1H), 7.43 (d, J= 8.8 Hz, 1H), 7.24 (dd, J= 8.0, 0.8 Hz, 1H), 7.01 (d, J= 8.0 Hz, 1H), 4.00 (s, 3H), 3.51 (t, J= 6.8 Hz, 2H), 2.97 (t, J= 8.0 Hz, 2H), 2.56 (s, 3H), 1.76 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 7.2 Hz, 2H), 1.27-1.40 (br, 15H); MS. m/z 366.2, [M+Na]+. 11- (5-fhioro-8-methoxyquinolin-2-yl)undecan-l-ol (C9) 'HNMR (400 MHz, ί/4-MeOD) 58.34 (d, J= 8.8 Hz, 1H), 7.51 (d, J= 8.8 Hz, 1H), 7.15 (d, J = 12 Hz, 1H), 6.93 (d, J= 3.2 Hz, 1H), 4.02 (s, 3H), 3.52 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 8.0 Hz, 2H), 1.81 (quin, J= 12 Hz, 2H), 1.48 (quin, J= 6.8 Hz, 2H), 1.13-1.37 (m, 15H); MS. m/z 370.2, [M+Na]+. 12- (5-fluoro-8-methoxyquinolin-2-yl)dodecan-l-ol (CIO) YD: 38%. Ή NMR (400 MHz, ί/4-MeOD) 58.36 (d, J= 8.8 Hz, 1H), 7.52 (d, J= 8.8 Hz, 1H), 7.17 (d, J= 8.8 Hz, 1H), 7.08 (dd, J= 8.4, 4.8 Hz, 1H), 4.04 (s, 3H), 3.53 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 1.78 (quin, J= 12 Hz, 2H), 1.51 (quin, J= 12 Hz, 2H), 1.28-1.42 (m, 17H); MS. m/z 384.2, [M+Na]+. 9-(5-chloro-8-methoxyquinolin-2-yl)nonan-l-ol (Cll) YD: 38%. Ή NMR (400 MHz, ί/4-MeOD) 58.47 (d, J= 8.8 Hz, 1H), 7.55 (d, J= 8.8 Hz, 1H), 7.52 (d, J= 8.4 Hz, 1H), 7.11 (d, J=8.8Hz, 1H), 4.04 (s, 3H), 3.51 (t, .7= 6.8 Hz, 2H), 3.00 (t,J = 8.0 Hz, 2H), 1.77 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.30-1.37 (m, 11H); MS. m/z 336.2, [M+H]+. ll-(5-chloro-8-methoxyquinolin-2-yl)undecan-l-ol (C12) YD: 35%. Ή NMR (400 MHz, ί/4-MeOD) 58.46 (d, J= 8.4 Hz, 1H), 7.54 (d, J= 8.8 Hz, 1H), 7.51 (d, J= 8.4 Hz, 1H), 7.10 (d, J= 8.4 Hz, 1H), 4.04 (s, 3H), 3.51 (t, J= 6.8 Hz, 2H), 2.99 (t, J = 8.0 Hz, 2H), 1.76 (quin, J= 7.6 Hz, 2H), 1.49 (quin, J= 6.8 Hz, 2H), 1.27-1.38 (br, 15H); MS. m/z 386.2, [M+Na]+. 15-(5-chloro-8-methoxyquinolin-2-yl)pentadecan-l-ol (C13) YD: 39%. l¥i NMR (400 MHz, ^-MeOD+CDCb) 58.44 (d, J= 8.4 Hz, 1H), 7.47 (d, J= 8.4 Hz, 1H), 7.46 (d, J= 8.4 Hz, 1H), 7.01 (dd, J= 8.4, 4.0 Hz, 1H), 4.03 (s, 3H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 8.0 Hz, 2H), 1.76 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.22-1.38 (m, 23H); MS. m/z 442.3, [M+Na]+. ll-(5-bromo-8-methoxyquinolin-2-yl)undecan-l-ol (C14) YD: 46%. l¥i NMR (400 MHz, CDC13) 58.40 (d, J= 8.4 Hz, 1H), 7.65 (d, J= 8.4 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 4.06 (s, 3H), 3.63 (t, J= 6.8 Hz, 2H), 3.07 (t, J = 8.0 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.55 (quin, J= 6.8 Hz , 2H), 1.30-1.45 (br, 15H); MS. m/z 430.2, [M+Na]+. ll-(8-methoxy-5-(trifluoromethyl)quinolin-2-yl)undecan-l-ol (C15) YD: 36%. Ή NMR (400 MHz, ^-MeOD+CDCb) 58.40 (dq, J= 10.4, 1.6 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.58 (d, J= 8.8 Hz, 1H), 7.20 (d, J=8.0Hz, 1H), 4.11 (s, 3H), 3.51 (t, .7= 6.8 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.27-1.43 (m, 15H); MS. m/z 420.2, [M+Na]+. 11-(5,8-dimethoxyquinolin-2-yl)undecan-l-ol (C16) YD: 31%; Ή NMR (400 MHz, ί/4-MeOD) 58.46 (d, J= 8.4 Hz, 1H), 7.38 (d, J= 8.4 Hz, 1H), 7.03 (d, J= 8.4 Hz, 1H), 6.82 (d, J= 8.4 Hz, 1H), 3.98 (s, 3H), 3.94 (s, 3H), 3.51 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 8.0 Hz, 2H), 1.73 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.27-1.35 (br, 15H); MS. m/z 360.2, [M+H]+. ll-(8-methoxy-6-methylquinolin-2-yl)undecan-l-ol (C17) YD: 41%. Ή NMR (400 MHz, CDCI3) 57.96 (d, J= 8.4 Hz, 1H), 7.30 (t, J= 8.4 Hz, 1H), 7.12 (s, 1H), 6.87 (s, 1H), 4.06 (s, 3H), 3.63 (t, J= 6.8 Hz, 2H), 3.05 (t, J= 7.6 Hz, 2H), 2.50 (s, 3H), 1.79 (quin, J= 8.0 Hz, 2H), 1.55 (quin, J= 6.8 Hz, 2H), 1.27-1.41 (br, 15H); MS. m/z 366.2, [M+Na]+. ll-(6-fhioro-8-methoxyquinolin-2-yl)undecan-l-ol (C18) YD: 41%; 'HNMR (400 MHz, ί/4-MeOD) 58.12 (d, J= 8.4 Hz, 1H), 7.44 (d, J= 8.8 Hz, 1H), 7.07 (dd, J= 9.2, 2.4 Hz, 1H), 7.01 (dd, J= 10.8, 2.8 Hz, 1H), 4.06 (s, 3H), 3.52 (t, J= 6.8 Hz, 2H), 2.95 (t, J= 8.0 Hz, 2H), 1.75 (quin, J= 7.6 Hz, 2H), 1.48 (quin, J= 7.2 Hz, 2H), 1.19-1.35 (m, 15H); MS. m/z 348.2, [M+H]+. ll-(6-chloro-8-methoxyquinolin-2-yl)undecan-l-ol (C19) YD: 39%; Ή NMR (400 MHz, <74-MeOD) 58.11 (d, J= 8.4 Hz, 1H), 7.44-7.47 (m, 2H), 7.13 (d, J= 2.0 Hz, 1H), 4.05 (s, 3H), 3.52 (t, J= 6.8 Hz, 2H), 2.96 (t, J= 8.0 Hz, 2H), 1.76 (quin, J = 7.2 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.28-1.36 (br, 15H); MS. m/z 360.2, [M+H]+. ll-(7-fhioro-8-methoxyquinolin-2-yl)undecan-l-ol (C20) YD: 32%; Ή NMR (400 MHz, ί/4-MeOD) 58.20 (d, J= 8.8 Hz, 1H), 7.60 (dd, J= 8.8, 5.6 Hz, 1H), 7.39 (dd, J= 8.8, 1.6 Hz, 1H), 7.01 (d, J= 8.8 Hz, 1H), 4.13 (d, J= 1.2 Hz, 3H), 3.52 (t, J = 6.8 Hz, 2H), 2.99 (t, J= 7.6 Hz, 2H), 1.80 (quin, J= 7.6 Hz, 2H), 1.48 (quin, J= 6.8 Hz, 2H), 1.29-1.42 (m, 15H); MS. m/z 348.2, [M+H]+. ll-(7-chloro-8-methoxyquinolin-2-yl)undecan-l-ol (C21) YD: 17%; Ή NMR (400 MHz, ί/4-MeOD) 58.20 (d, J= 8.4 Hz, 1H), 7.60 (d, J= 8.8 Hz, 1H), 7.50 (d, J= 8.8 Hz, 1H), 7.42 (d, J= 8.4 Hz, 1H), 4.08 (s, 3H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J = 7.6 Hz, 2H), 1.82 (quin, J= 7.2 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.28-1.42 (br, 15H); MS. m/z 360.2, [M+H]+. ll-(5-chloro-6,8-dimethoxyquinolin-2-yl)undecan-l-ol (C22) YD: 32%; Ή NMR (400 MHz, ί/4-MeOD) 58.40 (d, J= 8.8 Hz, 1H), 7.46 (d, J= 8.8 Hz, 1H), 7.07 (s, 1H), 4.08 (s, 3H), 4.02 (s, 3H), 3.51 (t, J= 6.8 Hz, 2H), 2.94 (t, J= 7.6 Hz, 2H), 1.74 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz , 2H), 1.27-1.34 (br, 15H); MS. m/z 394.2, [M+H]+. ll-(6-chloro-5,8-dimethoxyquinolin-2-yl)undecan-l-ol (C23) YD: 35%; 'HNMR (400 MHz, ί/4-MeOD) 58.38 (d, J= 8.8 Hz, 1H), 7.51 (d, J= 8.4 Hz, 1H), 7.12 (s, 1H), 4.02 (s, 3H), 3.94 (s, 3H), 3.52 (t, J= 6.4 Hz, 2H), 2.97 (t, J= 7.6 Hz, 2H), 1.74 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz , 2H), 1.34-1.41 (br, 15H); MS. m/z 394.2, [M+H]+. 11-(5,7-dichloro-8-methoxyquinolin-2-yl)undecan-l-ol (C24) YD: 40%. l¥i NMR (400 MHz, CDC13) 58.40 (d, J= 8.4 Hz, 1H), 7.59 (d, J= 8.0 Hz, 1H), 7.56 (s, 1H), 7.39 (d, J = 8.8 Hz, 1H), 4.19 (s, 3H), 3.63 (t, J= 6.8 Hz, 2H), 3.04 (t, J= 7.6 Hz, 2H), 1.84 (quin, J= 7.2 Hz, 2H), 1.55 (quin, J= 6.8 Hz , 2H), 1.27-1.40 (br, 15H); MS. m/z 420.2, [M+Na]+.
Example 3 - Preparation of (8-ethoxyquinol-2-yl) and (8-Isopropoxyquinol-2-yl)alkyl alcohols
Reagents and conditions: (a) Ethyl iodide or 2-bromopropane, K2CO3, DMF, 60 °C, 14 h.; (b) 1) LHMDS, THF, 0 °C, 1 h.; 2) Br(CH2)n-iOH, RT, 12 - 30 h.
Method: Ethyl iodide (3.9 g, 25.0 mmol) or 2-bromopropane (2.4 g, 19.2 mmol) was added to a stirred solution of 2-methylquinaldine (3.0 g, 18.8 mmol) and K2CO3 (6.5g, 47 mmol; 5.2 g, 37.6 mmol) in 30 ml DMF at 60 °C for 14 h. The reaction mixture was quenched by H2O (200 ml) and extracted with EtOAc (50 ml X 2). The organic layer was concentrated by evaporation in vacuum. The residue was purified by flash column chromatography with Hex/EA (6:1) and recrystallized with Hexane/EA to give 8-ethoxy-2-methylquinoline as intermediate (2.75g, 78%) in solid but liquid form for 8-isopropoxy-2-methylquinoline (2.92g, 77%). LHMDS (2.2 equiv.) was treated with a stirred solution of different intermediates in THF solution at 0 °C for 1 h. Corresponding Br(CH2)n-iOH (1.1 - 1.2 equiv.) was added to a reaction mixture and recover to RT for further 12 to 30 h. The solvent was removed under a reduced pressure. The brown oily residue was purified by flash column chromatography with Hex/EA or DCM/EA and recrystallized by Hexane/EA to afford compound D and E. 9- (8-ethoxyquinolin-2-yl)nonan-l-ol (Dl) YD: 45%. l¥i NMR (400 MHz, CDCb) 58.07 (d, J= 8.0 Hz, 1H), 7.34-7.42 (m, 3H), 7.06 (d, J = 8.4 Hz, 1H), 4.35 (q, J= 6.8 Hz, 2H), 3.63 (t, J= 6.8 Hz, 2H), 3.11 (br, 2H), 1.83 (quin, J= 7.6 Hz, 2H), 1.52-1.64 (m, 5H), 1.26-1.46 (br, 11H); MS. m/z 338.0, [M+Na]+. 10- (8-ethoxyquinolin-2-yl)decan-l-ol (D2) YD: 36%. Ή NMR (400 MHz, ί/4-MeOD) 58.16 (d, J= 8.4 Hz, 1H), 7.38-7.44 (m, 3H), 7.14 (dd, J= 12, 1.6 Hz, 1H), 4.29 (q, J= 6.8 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 7.6 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.57 (t, J= 7.6 Hz, 3H), 1.50 (t, J= 7.6 Hz, 2H), 1.30-1.43 (br, 13H); MS. m/z 352.0, [M+Na]+. 11- (8-ethoxyquinolin-2-yl)undecan-l-ol (D3) YD: 43%. 'HNMR (400 MHz, CDCb) 58.03 (d, J= 7.6 Hz, 1H), 7.31-7.41 (m, 3H), 7.04 (d, J = 12 Hz, 1H), 4.33 (q, J= 12 Hz, 2H), 3.62 (t, J= 6.4 Hz, 2H), 3.06 (br, 2H), 1.81 (quin, J= 8.0 Hz, 2H), 1.51-1.61(m, 6H), 1.38-1.51 (br, 14H); MS. m/z 344.3, [M+H]+. 12- (8-ethoxyquinolin-2-yl)dodecan-l-ol (D4) YD: 33%.¾ NMR (400 MHz, CDCb) 58.03 (d, J= 8.4 Hz, 1H), 7.31-7.39 (m, 3H), 7.04 (d, J = 7.6 Hz, 1H), 4.33 (q, J= 6.8 Hz, 2H), 3.62 (t, J= 6.4 Hz, 2H), 3.05 (t, J= 8.0 Hz, 2H), 1.82 (quin, J= 12 Hz, 2H)„ 1.53-1.62 (m, 5H), 1.27-1.42 (br, 17H); MS. m/z 380.3, [M+Na]+. 13- (8-ethoxyquinolin-2-yl)tridecan-l-ol (D5) YD: 43%. l¥i NMR (400 MHz, CDCb) 58.04 (d, J= 8.4 Hz, 1H), 7.32-7.40 (m, 3H), 7.04 (d, J = 7.6 Hz, 1H), 4.34 (q, J= 6.8 Hz, 2H), 3.62 (t, J= 6.4 Hz, 2H), 3.07 (t, J= 8.0 Hz, 2H), 1.82 (quin, J= 7.6 Hz, 2H), 1.52-1.62 (m, 5H), 1.19-1.46 (br, 19H); MS. m/z 394.0, [M+Na]+. 14- (8-ethoxyquinolin-2-yl)tetradecan-l-ol (D6) YD: 35%. l¥i NMR (400 MHz, CDCb) 58.00 (d, J= 8.4 Hz, 1H), 7.28-7.35 (m, 3H), 7.02 (d, J = 12 Hz, 1H), 4.32 (q, J= 6.8 Hz, 2H), 3.61 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.80 (quin, J= 7.6 Hz, 2H), 1.52-1.60 (m, 5H), 1.24-1.41 (br, 21H); MS. m/z 408.3, [M+Na]+. 15- (8-ethoxyquinolin-2-yl)pentadecan-l-ol (D7) YD: 33%. Ή NMR (400 MHz, ί/4-MeOD) 58.21 (d, J= 8.4 Hz, 1H), 7.40-7.47 (m, 3H), 7.17 (dd, J= 12, 1.6 Hz, 1H), 4.30 (q, J= 12 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.01 (t, J= 7.6 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.57 (t, J= 6.8 Hz, 3H), 1.51 (quin, J= 6.8 Hz, 2H), 1.26-1.43 (br, 23H); MS. m/z 400.4, [M+Na]+. ll-(8-ethoxy-5-methylquinolin-2-yl)undecan-l-ol (D8) YD: 34%. 'HNMR (400 MHz, CDC13) 58.20 (d, J= 8.8 Hz, 1H), 7.36 (d, J= 8.4 Hz, 1H), 7.19 (d, J= 7.6 Hz, 1H), 6.94 (d, J= 8.0 Hz, 1H), 4.31 (q, J= 6.8 Hz, 2H), 3.63 (t, J= 6.4 Hz, 2H), 3.08 (t, J= 8.0 Hz, 2H), 2.57 (s, 3H), 1.83 (quin, J= 7.6 Hz, 2H), 1.83 (t, J= 7.6 Hz, 3H), 1.57 (quin, J= 7.2 Hz, 2H), 1.41-1.45 (m, 2H), 1.28-1.33 (br, 13H); MS. m/z 380.2, [M+Na]+. ll-(8-ethoxy-5-fluoroquinolin-2-yl)undecan-l-ol (D9) YD: 49%. l¥i NMR (400 MHz, ί/4-MeOD) 58.33 (d, J= 8.4 Hz, 1H), 7.49 (d, J= 8.8Hz, 1H), 7.12 (t, J= 9.2 Hz, 1H), 7.05 (dd, J= 8.4, 4.8 Hz, 1H), 4.25 (q, J= 7.2 Hz, 2H), 3.51 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 8.0 Hz, 2H), 1.77 (quin, J= 7.2 Hz, 2H), 1.55 (t, J= 7.2 Hz, 3H), 1.48-1.52 (m, 2H), 1.28-1.46 (br, 15H); MS. m/z 384.2, [M+Na]+. 9-(5-chloro-8-ethoxyquinolin-2-yl)nonan-l-ol (DIO) YD: 34%. Ή NMR (400 MHz, ί/4-MeOD) 58.47 (d, J= 8.8 Hz, 1H), 7.55 (d, J= 8.8 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 7.10 (d, J= 8.8 Hz, 1H), 4.28 (q, J= 6.8 Hz, 2H), 3.51 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.76 (quin, J= 7.6 Hz, 2H), 1.56 (t, J= 6.8 Hz, 3H), 1.48-1.51 (m, 2H), 1.31-1.46 (br, 11H); MS. m/z 350.2, [M+H]+. ll-(5-chloro-8-ethoxyquinolin-2-yl)undecan-l-ol (Dll) YD: 38%. 'HNMR (400 MHz, CDCI3) 58.35 (d, J= 8.8 Hz, 1H), 7.36 (dd, J= 8.4, 3.6 Hz, 1H), 7.19 (d, J= 2.4 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 4.25 (q, J= 7.2 Hz, 2H), 3.56 (t, J= 6.4 Hz, 2H), 2.98 (t, J= 8.0 Hz, 2H), 1.76 (quin, J= 8.0 Hz, 2H), 1.45-1.54(m, 5H), 1.19-1.39 (br, 15H); MS. m/z 400.2, [M+Na]+. 15-(5-chloro-8-ethoxyquinolin-2-yl)pentadecan-l-ol (D12) YD: 38%. 'HNMR (400 MHz, ^-MeOD+CDCb) 58.47 (d, J= 8.8 Hz, 1H), 7.53 (d, J= 8.8 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.08 (d, J= 8.4 Hz, 1H), 4.28 (q, J= 6.8 Hz, 2H), 3.52 (t, J = 6.8 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.57 (t, J= 6.8 Hz, 3H), 1.49 (quin, J= 6.8 Hz, 2H), 1.25-1.41 (br, 23H); MS. m/z 434.3, [M+H]+. ll-(5-bromo-8-ethoxyquinolin-2-yl)undecan-l-ol (D13) YD: 33%.¾ NMR (400 MHz, ί/4-MeOD) 5 8.41 (d, J= 8.8 Hz, 1H), 7.67 (d, J= 8.4Hz, 1H), 7.52 (d, J= 8.8 Hz, 1H), 7.04 (d, J= 8.4 Hz, 1H), 4.27 (q, J= 12 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 1.77 (quin, J= 7.6 Hz, 2H), 1.56 (t, J= 12 Hz, 3H), 1.47-1.57 (m, 2H), 1.27-1.39 (br, 15H); MS. m/z 444.2, [M+Na]+. 11-(5,7-dichloro-8-ethoxyquinolin-2-yl)undecan-l-ol (D14) YD: 34%. Ή NMR (400 MHz, ί/4-MeOD) 58.43 (d, J= 8.8 Hz, 1H), 7.64 (s, 1H), 7.51 (d, J = 8.4 Hz, 1H), 4.39 (q, J= 6.8 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 12 Hz, 2H), 1.84 (quin, J= 12 Hz, 2H), 1.45-1.49 (m, 5H), 1.27-1.36 (br, 15H); MS. m/z 434.2, [M+Na]+. 9-(8-isopropoxyquinolin-2-yl)nonan-l-ol (El) YD: 28%. 'HNMR (400 MHz, ί/4-MeOD) δ 8.07 (d, J= 8.8 Hz, 1H), 7.33-7.36 (m, 1H), 7.31 7.33 (m, 2H), 7.09 (d, J= 12 Hz, 1H), 4.79 (m, 1H), 3.49 (t, J= 6.8 Hz, 2H), 2.93 (t, J= 7.6 Hz, 2H), 1.71 (quin, J= 7.6 Hz, 2H), 1.45-1.49 (m, 2H), 1.41 (d,J=6Hz, 6H), 1.20-1.35 (br, 11H); MS. m/z 330.2, [M+H]+. 10- (8-isopropoxyquinolin-2-yl)decan-l-ol (E2) YD: 36%. 'HNMR (400 MHz, ί/4-MeOD) δ 8.14 (d, J= 8.8 Hz, 1H), 7.40-7.43 (m, 1H), 7.377.39 (m, 2H), 7.16 (dd, J= 6.8, 2.0 Hz, 1H), 4.83 (m, 1H), 3.51 (t, J= 6.8 Hz, 2H), 2.98 (t, J = 7.6 Hz, 2H), 1.77 (quin, J= 12 Hz, 2H), 1.45-1.49 (m, 2H), 1.41 (d, J= 6 Hz, 6H), 1.20-1.35 (br, 11H); MS. m/z 366.0, [M+Na]+. 11- (8-isopropoxyquinolin-2-yl)undecan-l-ol (E3) YD: 45 %. l¥i NMR (400 MHz, CDCb) 51.99 (d, J= 8.4 Hz, 1H), 7.34 (d, J= 4.4 Hz, 2H), 7.247.27 (m, 1H), 7.09 (t, J= 4.4 Hz, 1H), 4.82 (sept, J= 6 Hz, 1H), 3.60 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 7.6 Hz, 2H), 1.81 (quin, J= 7.6 Hz, 2H), 1.51-1.56 (m, 2H), 1.47 (d, J= 6 Hz, 6H), 1.33-1.43 (br, 15H); MS. m/z 380.3, [M+Na]+. 12- (8-isopropoxyquinolin-2-yl)dodecan-l-ol (E4) YD: 34 %. 'HNMR (400 MHz, CDCb) δ8.05 (d, J= 7.6 Hz, 1H), 7.30-7.39 (m, 3H), 7.13 (dd, J = 6.4, 2.4 Hz, 1H), 4.85 (sept, J= 6 Hz, 1H), 3.63 (t, J= 6.8 Hz, 2H), 3.09 (br, 2H), 1.84 (quin, J = 7.6 Hz, 2H), 1.56 (quin, J= 12 Hz, 2H), 1.48 (d, J= 6 Hz, 6H), 1.27-1.47 (br, 17H); MS. m/z 394.3, [M+Na]+. 13- (8-isopropoxyquinolin-2-yl)tridecan-l-ol (E5) YD: 34%. !H NMR (400 MHz, ί/4-MeOD) δ 8.11 (d,J= 8.4 Hz, 1H), 7.35-7.41 (m, 3H), 7.14 (d, J= 12 Hz, 1H), 4.81 (br, 1H), 3.52 (t, J= 6.8 Hz, 2H), 2.96 (t, J= 8.0 Hz, 2H), 1.75 (quin, J = 12 Hz, 2H), 1.45-1.52 (m, 2H), 1.43 (d, J= 6.0 Hz, 6H), 1.25-1.42 (br, 19H); MS. m/z 408.0, [M+Na]+. 14- (8-isopropoxyquinolin-2-yl)tetradecan-l-ol (E6) YD: 36%. Ή NMR (400 MHz, ί/4-MeOD) 68.13 (d, J= 8.8 Hz, 1H), 7.37-7.43 (m, 3H), 7.16 (dd, J= 12, 1.6 Hz, 1H), 4.86 (br, 1H), 3.52 (t, J= 6.8 Hz, 2H), 2.98 (t, J= 7.6 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.49-1.52 (m, 2H), 1.46 (d, J= 6.4 Hz, 6H), 1.26-1.41 (br, 21H); MS. m/z 422.3, [M+Na]+. 15- (8-isopropoxyquinolin-2-yl)pentadecan-l-ol (E7) YD: 36%. 'HNMR (400 MHz, CDCb) 68.01 (d, J= 8.4 Hz, 1H), 7.27-7.36 (m, 3H), 7.10-7.13 (m, 1H), 4.82 (sept, J= 4.1 Hz, 1H), 3.61 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 6.4 Hz, 2H), 1.81 (quin, J= 7.6 Hz, 2H), 1.52-1.55 (m, 2H), 1.48 (d, J= 2 Hz, 6H), 1.31-1.47 (br, 21H); MS. m/z 436.3, [M+Na]+. ll-(8-isopropoxy-5-methylquinolin-2-yl)undecan-l-ol (E8) YD: 48%. 'HNMR (400 MHz, CDC13) 58.09 (d, J= 8.4 Hz, 1H), 7.26 (d, J= 8.8 Hz, 1H), 7.12 (d, J= 8.0 Hz, 1H), 6.97 (t, J= 7.6 Hz, 1H), 4.75 (sept, J= 6 Hz, 1H), 3.55 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 7.6 Hz, 2H), 2.51 (s, 3H), 1.81 (t, J= 12 Hz, 2H), 1.23-1.49 (br, 23H); MS. m/z 394.3, [M+Na]+. ll-(5-fluoro-8-isopropoxyquinolin-2-yl)undecan-l-ol (E9) YD: 46%. l¥i NMR (400 MHz, ί/4-MeOD) 58.30 (d, J= 8.8 Hz, 1H), 7.44 (d, J= 8.4 Hz, 1H), 7.09 (d, J= 4.8 Hz, 1H), 4.79 (m, 1H), 3.51 (t, J= 6.8 Hz, 2H), 2.97 (t, J= 8.0 Hz, 2H), 1.74 (quin, J= 7.6 Hz, 2H), 1.45-1.51 (m, 2H), 1.42 (d, J= 6.4 Hz, 6H), 1.12-1.39 (br, 15H); MS. m/z 398.2, [M+Na]+. 9-(5-chloro-8-isopropoxyquinolin-2-yl)nonan-l-ol (E10) YD: 46%. l¥i NMR (400 MHz, ί/4-MeOD) 58.45 (d, J= 8.8 Hz, 1H), 7.52 (d, J= 8.4 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.12 (d, J= 8.4 Hz, 1H), 4.85 (m, 1H), 3.51 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.49 (quin, J= 6.4 Hz, 2H), 1.45 (d, J= 6.0 Hz, 6H), 1.30-1.42 (br, 11H); MS. m/z 364.2, [M+H]+. ll-(5-chloro-8-isopropoxyquinolin-2-yl)undecan-l-ol (Ell) YD: 46%. l¥i NMR (400 MHz, ί/4-MeOD) 58.47 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 7.13 (d, J= 8.4 Hz, 1H), 4.89 (m, 1H), 3.52 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 12 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.48 (quin, J= 6.8 Hz, 2H), 1.41 (d, J= 5.6 Hz, 6H), 1.21 ~ 1.39 (br, 15H); MS. m/z 414.2, [M+Na]+. 15-(5-chloro-8-isopropoxyquinolin-2-yl)pentadecan-l-ol (E12) YD: 46%. Ή NMR (400 MHz, d4-MeOD +CDCI3) 58.46 (d, J= 8.8 Hz, 1H), 7.51 (d, J= 8.8 Hz, 1H), 7.48 (d, J= 8.8 Hz, 1H), 7.11 (d, J= 8.4 Hz, 1H), 4.85 (m, 1H), 3.52 (t, J= 6.8 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.79 (quin, J= 12 Hz, 2H), 1.51 (quin, J= 6.8 Hz, 2H), 1.46 (d, J = 6.0 Hz, 6H), 1.25-1.39 (m, 23H); MS. m/z 448.3, [M+H]+. ll-(5-bromo-8-isopropoxyquinolin-2-yl)undecan-l-ol (E13) YD: 40%. l¥i NMR (400 MHz, ί/4-MeOD) 58.43 (d, J= 8.8 Hz, 1H), 7.69 (d, J= 8.8 Hz, 1H), 7.52 (d, J= 8.4 Hz, 1H), 7.10 (d, J= 7.6 Hz, 1H), 4.86 (br, 1H), 3.52 (t, J= 6.8 Hz, 2H), 3.02 (t, J= 7.6 Hz, 2H), 1.79 (quin, J= 12 Hz, 2H), 1.50-1.52 (m, 2H), 1.46 (d, J= 6.0 Hz, 6H), 1.28 1.41 (br, 15H); MS. m/z 458.2, [M+Na]+. 11-(5,7-dichloro-8-isopropoxyquinolin-2-yl)undecan-l-ol (E14) YD: 37%. Ή NMR (400 MHz, CDCI3) 58.36 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 3.2 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 5.13 (m, 1H), 3.63 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 7.6 Hz, 2H), 1.86 (quin, J = 6.8 Hz, 2H), 1.52-1.59 (m, 4H), 1.27-1.44 (br, 20H); MS. m/z 448.4, [M+Na]+.
Example 4- Preparation of (8-cyclopropylmethoxyquinol-2-yl)alkyl alcohol derivatives
Reagents and conditions: (a) Methylenecyclopropyl bromide, K2CO3, DMF, 60 °C, 13 h.; (b) 1) LHMDS, THF, 0 °C, 1 h.; 2) Br(CH2)n-iOH, rt, 12 - 20 h.
Method: Methylenecyclopropyl bromide (1.0 g, 6.3 mmol) was added to a stirred solution of 2-methylquinaldine (1.0 g, 6.3 mmol) and K2CO3 (2.5 g, 18.1 mmol) in 25 ml DMF at 60 °C for 13 h. The reaction mixture was quenched by H2O (200 ml) and extracted with EtOAc (30 ml X 3). The organic layer was concentrated by evaporation in vacuum and the residue purified by flash column chromatography with Hex/EA (8:1 to 6:1) to give 5-chloro-8-(cyclopropylmethoxy)-2-methylquinoline as intermediate. LHMDS (2.2 equiv.) was treated with a stirred solution of intermediate (0.5 g, 2.3 mmol) in THF solution at 0 °C for 1 h.
Corresponding Br(CH2)n-iOH (1.1 - 1.2 equiv.) was added to reaction mixture and recover to RT for further 12 to 20 h. The solvent was removed under a reduced pressure. The brown oily residue was purified by flash column chromatography with Hex/EA or DCM/EA and recrystallized by Hex/EA to afford compound F. 9- (8-(cyclopropylmethoxy)quinolin-2-yl)nonan-l-ol (FI) YD: 49%. 'HNMR (400 MHz, ί/4-MeOD) 58.15 (d, J= 8.4 Hz, 1H), 7.38-7.43 (m, 3H), 7.14 (dd, J= 5.6, 3.2 Hz, 1H), 4.06 (d, J= 12 Hz, 2H), 3.51 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 1.77 (quin, J= 7.6 Hz, 2H), 1.48-1.52 (m, 3H), 1.32-1.47 (m, 11H), 0.65-0.70 (m, 2H), 0.340.45 (m, 2H); MS. m/z 342.2, [M+H]+. 10- (8-(cyclopropylmethoxy)quinolin-2-yl)decan-l-ol (F2) YD: 43%. 'HNMR (400 MHz, ί/4-MeOD) 58.16 (d, J= 8.4 Hz, 1H), 7.40 ~ 7.43 (m, 3H), 7.15 (dd, J= 5.6, 3.2 Hz, 1H), 4.07 (d, J= 12 Hz, 2H), 3.52 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 8.0 Hz, 2H), 1.80 (quin, J= 7.6 Hz, 2H), 1.47-1.53 (m, 3H), 1.31-1.44 (m, 13H), 0.67-0.69 (m, 2H), 0.440.46 (m, 2H); MS. m/z 356.2, [M+H]+. 11- (8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol (F3) YD: 45%. l¥i NMR (400 MHz, CDCI3) 58.02 (d, J= 8.4 Hz, 1H), 7.30 ~ 7.38 (m, 2H), 7.05 (dd, J= 6.4, 2.4 Hz, 1H), 4.11 (d, J= 6.8 Hz, 1H), 3.63 (t, J= 6.4 Hz, 2H), 3.04 (t, J= 8.0 Hz, 2H), 1.83 (quin, J= 7.6 Hz, 2H), 1.48-1.59 (m, 3H), 1.26-1.46 (br, 15H), 0.67 (dd, J= 13.2, 5.6 Hz, 2H), 0.44 (dd, J= 13.2, 5.6 Hz, 2H); MS. m/z 392.2, [M+Na]+. 12- (8-(cyclopropylmethoxy)quinolin-2-yl)dodecan-l-ol (F4) YD: 36%. 'HNMR (400 MHz, CDCI3) 58.01 (d, J= 8.4 Hz, 1H), 7.29-7.38 (m, 3H), 7.06 (dd, J = 6.0, 2.4 Hz, 1H), 4.11 (d, J= 6.8 Hz, 1H), 3.63 (t, J= 6.4 Hz, 2H), 3.04 (t, J= 12 Hz, 2H), 1.83 (quin, J= 7.6 Hz, 2H), 1.48-1.59 (m, 3H), 1.27-1.47 (br, 17H), 0.67 (dd, J= 13.2, 5.6 Hz, 2H), 0.42-0.48 (m, 2H); MS. m/z 384.3, [M+H]+. 13- (8-(cyclopropylmethoxy)quinolin-2-yl)tridecan-l-ol (F5) YD: 42%. 'HNMR (400 MHz, ί/4-MeOD) 58.14 (d, J= 8.4 Hz, 1H), 7.38 ~ 7.41 (m, 3H), 7.05 (dd, J= 5.6, 3.2 Hz, 1H), 4.05 (d, J= 6.8 Hz, 2H), 3.52 (t, J= 6.4 Hz, 2H), 2.99 (t, J= 8.0 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H),1.44-1.52 (m, 3H), 1.26-1.40 (m, 19H), 0.67 (dd, J= 13.2, 5.6 Hz, 2H), 0.40-0.47 (m, 2H); MS. m/z 420.0, [M+Na]+. 14- (8-(cyclopropylmethoxy)quinolin-2-yl)tetradecan-l-ol (F6) YD: 37%. 'HNMR (400 MHz, ί/4-MeOD) 58.15 (d, J= 8.8 Hz, 1H), 7.39 ~ 7.42 (m, 3H), 7.13 (dd, J= 5.6, 3.2 Hz, 1H), 4.05 (d, J= 6.8 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 7.6 Hz, 2H), 1.78 (quin, J= 7.6 Hz, 2H), 1.44-1.52 (m, 3H), 1.26-1.43 (m, 21H), 0.65-0.69 (m, 2H), 0.42 (dd, J= 10.0, 4.8 Hz, 2H); MS. m/z 434.3, [M+Na]+. 15- (8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-l-ol (F7) YD: 69%. 'HNMR (400 MHz, ί/4-MeOD+CDCb) 58.13 (dd, J= 8.4, 2.0 Hz, 1H), 7.38 (br, 3H), 7.11 (d, J= 2.4 Hz, 1H), 4.05 (d, J= 6.8 Hz, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 8.0 Hz, 2H), 1.78 (quin, J= 7.2 Hz, 2H),1.46-1.52 (m, 3H), 1.25-1.44 (m, 23H), 0.63-0.69 (m, 2H), 0.400.46 (m, 2H); MS. m/z 426.4, [M+H]+. ll-(8-(cyclopropylmethoxy)-5-methylquinolin-2-yl)undecan-l-ol (F8) YD: 45%. 'HNMR (400 MHz, ί/4-MeOD) 58.31 (d, J= 8.8 Hz, 1H), 5 7.44 (d, J= 8.8 Hz, 1H), 7.22 (d, J= 8.0 Hz, 1H), 7.02 (d, J= 8.0 Hz, 1H), 4.02 (d, J= 12 Hz, 2H), 3.52 (t, J= 6.4 Hz, 2H), 3.00 (t, J= 8.0 Hz, 2H), 2.57 (s, 3H), 1.79 (quin, J= 12 Hz, 2H), 1.29-1.52 (m, 18H), 0.65 -0.68 (m, 2H), 0.40-0.43 (m, 2H); MS. m/z 406.3, [M+Na]+. ll-(8-(cyclopropylmethoxy)-5-fhioroquinolin-2-yl)undecan-l-ol (F9) YD: 46%. 'HNMR (400 MHz, ί/4-MeOD) 58.36 (d, J= 8.8 Hz, 1H), 7.52 (d, J= 8.8 Hz, 1H), 7.07-7.15 (m, 2H), 4.05 (d, J= 6.8 Hz, 2H), 3.53 (t, J= 6.8 Hz, 2H), 3.02 (t, J= 7.6 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.42-1.49 (m, 3H), 1.22-1.40 (m, 15H), 0.65-0.69 (m, 2H), 0.42 (dd, J= 10.4, 4.8 Hz, 2H); MS. m/z 410.2, [M+Na]+. 9-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)nonan-l-ol (F10) YD: 33%. 'HNMR (400 MHz, ί/4-MeOD) 58.48 (d, J= 8.8 Hz, 1H), 7.55 (d, J= 8.8 Hz 1H), 7.49 (d, J= 8.4 Hz, 1H), 7.11 (d, ./= 8.4 Hz, 1H), 4.06 (d, J= 6.8 Hz, 2H), 3.51 (t, ./= 6.4 Hz, 2H), 3.03 (t, J= 8.0 Hz, 2H), 1.83 (t, J= 7.6 Hz, 2H), 1.54-1.69 (m, 3H), 1.27-1.48 (br, 15H), 0.67-0.71 (m, 2H), 0.43-0.46 (m, 2H); MS. m/z 376.2, [M+H]+. ll-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol (Fll) YD: 34%. 'HNMR (400 MHz, CDC13) 58.41 (d, J= 8.8 Hz, 1H), 7.43 (d, J= 2.4Hz 1H), 7.41 (d, J= 2.4 Hz, 1H), 6.97 (d, J= 8.4 Hz, 1H), 4.09 (d, J= 12 Hz, 2H), 3.63 (t, J= 6.4 Hz, 2H), 3.05 (t, J= 8.0 Hz, 2H), 1.83 (t, J= 7.6 Hz, 2H), 1.54-1.69 (m, 3H), 1.27-1.48 (br, 15H), 0.670.71 (m, 2H), 0.43 -0.46 (m, 2H); MS. m/z 426.2, [M+Na]+. 15-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-l-ol (F12) YD: 28%. l¥i NMR (400 MHz, ^-MeOD+CDCb) 58.47 (d, J= 8.8 Hz, 1H), 7.54 (d, J= 8.8 Hz, 1H), 7.48 (d, J= 8.4 Hz, 1H), 7.10 (d, J= 8.4 Hz, 1H), 4.06 (d, J= 6.8 Hz, 2H), 3.52 (t, J = 6.8 Hz, 2H), 3.02 (t, J= 7.6 Hz, 2H), 1.79 (quin, J= 7.6 Hz, 2H), 1.46-1.52 (m, 2H), 1.25-1.44 (br, 24H), 0.65-0.69 (m, 2H), 0.41-0.43 (m, 2H); MS. m/z 460.3, [M+Na]+. ll-(5-bromo-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol (F13) YD: 35%. l¥i NMR (400 MHz, ί/4-MeOD) 58.42 (d, J= 8.8 Hz, 1H), 5 7.67 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 8.8 Hz, 1H), 7.06 (d, J= 8.4 Hz, 1H), 4.05 (d, J= 12 Hz, 2H), 3.51 (t, J= 6.4 Hz, 2H), 3.02 (t, J= 8.0 Hz, 2H), 1.77 (quin, J= 7.6 Hz, 2H), 1.46-1.52 (m, 3H), 1.28-1.44 (m, 15H), 0.65-0.70 (m, 2H), 0.42-0.45 (m, 2H); MS. m/z 470.2, [M+Na]+. 11-(5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol (F14) YD: 53%. Ή NMR (400 MHz, ί/4-MeOD) 58.47 (d, J= 8.8 Hz, 1H), 5 7.67 (s, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.06 (d, J= 8.4 Hz, 1H), 4.23 (d, J= 12 Hz, 2H), 3.53 (t, J= 6.4 Hz, 2H), 3.02 (t, J = 7.6 Hz, 2H), 1.86 (quin, J= 12 Hz, 2H), 1.48-1.53 (m, 2H), 1.29-1.38 (m, 16H), 0.62 (dd, J = 12.8, 5.2 Hz, 2H), 0.31 (dd, J= 10.8, 5.2 Hz, 2H); MS. m/z 460.2, [M+Na]+.
Example 5 - Preparation of (5,7-dichloro-8-hydroxyquinol-2-yl)alkyl alcohol
Reagents and conditions: (a) NCS, CHCb, rt, 48 h.
Method: N-chlorosuccinimide (0.3 g, 2.25 mmol) was added to a stirred solution of compounds B in CHCI3 (20 ml) for 48 h. The reaction mixture was poured into crushed ice and extracted with CH2CI2 (20ml X 2). The extract was purified by column chromatography with Hex/EA (3:1) and recrystallized to give compound G1 (0.18g, 49%). 5,7-dichloro-2-(ll-hydroxyundecyl)quinolin-8-ol (Gl) YD: 49%. Ή NMR (400 MHz, CDCI3) 58.38 (d, J= 8.8 Hz, 1H), 7.51 (s, 1H), 7.42 (d, J = 8.8 Hz, 1H), 3.63 (t, J= 6.8 Hz, 2H), 3.00 (t, J= 7.6 Hz, 2H), 1.82 (quin, J= 12 Hz, 2H), 1.56 (quin, J= 7.6 Hz , 2H), 1.27-1.38 (br, 15H); MS. m/z 382.0, [M-H]+.
Example 6 - Preparation of (5-chloro-8-methoxyquinol-2-yl)alkyl alcohol or alkylacetate
Reagents and conditions: (a) HC1, ICI3, glacial HOAc, H2O, 6 h, rt.
Method: To a various long chain substituted (8-methoxyquinolin-2-yl)-ol (1.0 eq.) was added cone. HC1 (0.5 mL/mmol) at RT and the reddish yellow mixture was stirred for 5 minutes. To this mixture was added dropwise a solution of ICI3 (1.5 eq.) in cone. HC1 (2 mL). The yellow gummy mixture was stirred at RT for 6 h. Water was added to it and partitioned with EA.
Organic layer was washed with brine, drying on anhydrous MgS04 and filtered followed by solvent removal, yielded oily residue purified by flash column chromatography using CHCI3 to yield HI to H5. 10-(5-Chloro-8-methoxyquinolin-2-yl)decan-l-ol (Hla) and acetic acid 10- (5-chloro-8-methoxyquinolin-2-yl)decyl ester (Hlb). YD: 61% and 10%. Hla: Ή NMR (200 MHz, CDCI3) 58.41 (d, J = 8.68 Hz, 1H), 7.42 (dd, J = 8 Hz , J = 2 Hz , 2H), 6.91 (d, J = 8 Hz , 1H), 4.03 (s, 3H), 3.59 (t, J = 6 Hz , 2H), 3.59 (t, J = 4 Hz , 2H), 1.73 (m, 2H), 1.48 (m, 2H), 1.25 (br, 12H); HRMS (El): Calcd for C2oH28C1N02:349.1803, Found:349.1781. Hlb: Ή NMR (400 MHz, CDCI3) 58.41 (d, J = 8 Hz, 1H), 7.42 (dd, J = 8 Hz , J = 4Hz , 2H), 6.92 (d, J = 8 Hz , 1H), 4.06 (t, J = 8 Hz , 2H), 4.02 (s, 3H), 3.03 (t, J = 8 Hz, 2H), 2.02 (s, 3H), 1.79 (m, 2H), 1.59 (m, 2H), 1.40 (m, 2H), 1.23 (br, 12H); HRMS (FAB, M + H): Calcd for C22H31CINO3 392.1992, Found 392.1983. 11- (5-Chloro-8-methoxyquinolin-2-yl)undecan-l-ol (H2a) and acetic acid ll-(5-chloro-8-methoxyquinolin-2-yl)undecyl ester (H2b) YD: 60% and 12%. H2a: Ή NMR (400 MHz, CDCI3) 58.43 (d, J = 8.72 Hz, 1H), 7.44 (dd, J = 13.5 Hz , J = 5.3 Hz , 2H), 6.94 (d, J = 8.3 Hz , 1H), 4.05 (s, 3H), 3.62 (t, J = 6.6 Hz,2H), 3.07 (t, J = 5.2 Hz , 2H), 1.80 (m, 2H), 1.54 (m, 2H), 1.39 (m, 2H), 1.26 (br, 12H); HRMS (El): Calcd for C21H30CINO2 363.1960, Found 363.1941. H2b: Ή NMR (400 MHz, CDCI3) 58.41 (d, J = 8.6 Hz, 1H), 7.42 (dd, J = 8.3 Hz, J = 3.8 Hz, 2H), 6.91(d, J = 8.4 Hz, 1H), 4.06 (t, J = 7.8 Hz, 2H), 4.02 (s, 3H), 3.02 (t, J = 7.8 Hz, 2H), 2.01 (s, 3H), 1.78 (m, 2H), 1.58 (m, 2H), 1.39 (m, 2H), 1.22 (br, 12H); HRMS (El): Calcd for C23H32CINO3 405.2065, Found 405.2044. 12- (5-Chloro-8-methoxyquinolin-2-yl)dodecan-l-ol (H3a) and acetic acid 12-(5-chloro-8-methoxyquinolin-2-yl)dodecyl ester (H3b) YD: 57% and 27%. H3a: Ή NMR (400 MHz, CDCI3) 58.46 (d, J = 8.6 Hz, 1H), 7.44 (dd, J = 8.3 Hz, J = 6.9 Hz, 2H), 6.94(d, J = 8.4 Hz, 1H), 4.04 (s, 3H), 3.59 (t, J = 6.6 Hz, 2H), 3.11 (t, J = 7.8 Hz, 2H), 1.78 (m, 2H), 1.50 (m, 2H), 1.40 (m, 2H), 1.23 (br, 14H); HRMS (El): Calcd for C22H32CINO2 377.2116, Found 377.2106. H3b: Ή NMR (200 MHz, CDCI3) 58.38 (d, J = 8.7 Hz, 1H), 7.40 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.4 Hz, 1H), 4.03 (t, J = 7.8 Hz, 2H), 4.01 (s, 3H), 3.02 (t, J = 7.8 Hz, 2H), 1.99 (s, 3H), 1.76 (m, 2H), 1.59 (m, 2H), 1.20 (br, 16H); HRMS (FAB, M+H): Calcd for C24H35CINO3 420.2305, Found 420.2310. 13-(5-Chloro-8-methoxyquinolin-2-yl)tridecan-l-ol (H4a) and acetic acid 13-(5-chloro-8-methoxyquinolin-2-yl)tridecyl ester (H4b) YD: 64% and 14%. H4a: Ή NMR (400 MHz, CDC13) 58.46 (d, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.3 Hz, J = 6.9 Hz, 2H), 6.94(d, J = 8.4 Hz, 1H), 4.04 (s, 3H), 3.59 (t, J = 6.6 Hz, 2H), 3.11 (t, J = 7.8 Hz, 2H), 1.78 (m, 2H), 1.50(m, 2H), 1.40 (m, 2H), 1.23 (br, 16H); HRMS (El): Calcd for C23H34CINO2 391.2273, Found 391.2249. H4b: Ή NMR (400 MHz, CDCI3) 5 8.38 (d, J = 8.6 Hz, 1H), 7.40 (dd, J = 8.5 Hz, J = 5.8 Hz, 2H), 6.89(d, J = 8.4 Hz, 1H), 4.01(t, J = 9.6 Hz, 2H), 4.00 (s, 3H), 3.00 (t, J = 7.9 Hz, 2H), 1.99 (s, 3H), 1.75 (m, 2H), 1.58 (m, 2H), 1.38 (m, 2H), 1.22 (br, 16H); HRMS (FAB, M + H): Calcd for C25H37CINO3 434.2462, Found 434.2459. Example 7 - Preparation of (8-hydroxyquinol-4-yl) or (8-alkoxyquinol-4-yl) alkyl alcohols
Reagents and conditions: (a) methyl vinyl ketone, HC1, reflux, (b) Mel, K2CO3, acetone, rt, 8h; EtI or 2-bromopropane or methylenecyclopropyl bromide, K2CO3, DMF, 60 °C, (c) 1) LHMDS, THF, 0 °C, 1 h.; 2) Br(CH2)„-iOH, rt, (d) BnBr, KOH, EtOH, reflux, (e) H2, Pd/C, MeOH, rt, 24 h.
Method: The intermediate INT 1 was synthesized through ring closure from 2-aminophenol reacted with methylvinyl ketone. INT 1 was reacted with various alkyl halides to afford 8-alkoxy-4-methylquinoline derivatives as intermediates. Corresponding Br(CH2)n-iOH was reacted with intermediates to synthesize series of compounds J and I. The protective group J was removed by hydrogenation (method illustrated in example 1) to obtain compound K. ll-(8-methoxyquinolin-4-yl)undecan-l-ol (II) YD: 34%. 'HNMR (400 MHz, CDCI3) 58.80 (dd, J= 4.4, 0.6 Hz, 1H), 7.59 (dd, J= 8.4, 0.8 Hz, 1H), 7.44-7.49 (m, 1H), 7.03 (d, J = 7.6 Hz, 1H), 4.08 (s, 3H), 3.63 (t, J= 6.8 Hz, 2H), 3.03 (t, J = 7.6 Hz, 2H), 1.74 (quin, J= 7.6 Hz, 2H), 1.55 (quin, J= 7.2 Hz, 2H), 1.23-1.45 (br, 15H); MS. m/z 329.9, [M+H]+. ll-(8-ethoxyquinolin-4-yl)undecan-l-ol (12) YD: 42%. H NMR (400 MHz, ί/4-MeOD) 58.66 (d, J= 8.4 Hz, 1H), 7.64 (d, J= 8.4 Hz, 1H), 7.51 (t, J= 8.0 Hz, 1H), 7.37 (d, J= 8.4 Hz, 1H), 7.15 (d, J= 7.6 Hz, 1H), 4.27 (q, J= 6.8 Hz, 2H), 3.52 (t,J= 6.8 Hz, 2H), 3.08 (d, J= 7.6 Hz, 2H), 1.75 (quin, J= 7.6 Hz, 2H), 1.50-1.57 (m, 5H), 1.21-1.49 (br, 15H); MS. m/z 366.2, [M+Na]+. ll-(8-isopropoxyquinolin-4-yl)undecan-l-ol (13) YD: 48%. l¥i NMR (400 MHz, ί/4-MeOD) 5 8.65 (d, J= 8.4 Hz, 1H), 7.63 (d,J= 7.6 Hz, 1H), 7.51 (d, J= 8.0 Hz, 1H), 7.35 (d, J= 4.4 Hz, 1H), 7.17 (d, J= 8.0 Hz, 1H), 4.84 (br, 1H), 3.52 (t, J= 6.4 Hz, 2H), 3.07 (d, J= 7.6 Hz, 2H), 1.74 (br, 2H), 1.43-1.50 (br, 9H), 1.29-1.34 (br, 14H); MS. m/z 380.3, [M+Na]+. ll-(8-(cyclopropylmethoxy)quinolin-4-yl)undecan-l-ol (14) YD: 53%. l¥i NMR (400 MHz, ί/4-MeOD) 58.66 (d, J= 8.4 Hz, 1H), 7.63 (d, J= 8.4 Hz, 1H), 7.49 (t, J= 8.4 Hz, 1H), 7.36 (d, J= 4.8 Hz, 1H), 7.13 (d, J= 7.6 Hz, 1H), 4.03 (d, J= 6.8 Hz, 1H), 3.52 (t, J= 6.8 Hz, 2H), 3.06 (d, J= 7.6 Hz, 2H), 1.69-1.75 (m, 2H), 1.28-1.52 (br, 18H), 0.65-0.68 (m, 2H), 0.42-0.43 (m, 2H); MS. m/z 392.2 [M+Na]+. 11- (8-(benzyloxy)quinolin-4-yl)undecan-l-ol (Jl) YD: 46%. l¥i NMR (400 MHz, ί/4-MeOD) 5 8.66 (d, J= 8.4 Hz, 1H), 7.64 (d,J = 8.4 Hz, 1H), 7.52 (d,J= 7.2 Hz, 2H), 7.45 (t, J= 8.0 Hz, 1H), 7.30-7.38 (m, 3H), 7.26-7.28 (m, 1H), 7.17 (d, J= 7.6 Hz, 1H), 5.37 (s, 2H), 3.52 (t, J= 6.4 Hz, 2H), 3.06 (t, J= 8 Hz, 2H), 1.73 (q, J= 7.6 Hz, 2H), 1.50 (t, J= 7.2 Hz, 2H), 1.28-1.48 (m, 15H); MS. m/z 428.3, [M+Na]+. 12- (8-(benzyloxy)quinolin-4-yl)dodecan-l-ol (J2) YD: 46%. l¥i NMR (400 MHz, ί/4-MeOD) 5 8.67 (d, J= 4.4 Hz, 1H), 7.65 (d,J = 8.4 Hz, 1H), 7.52 (d,J= 7.2 Hz, 2H), 7.45 (t, J= 8.0 Hz, 1H), 7.30-7.39 (m, 3H), 7.27-7.30 (m, 1H), 7.18 (d, J= 8.0 Hz, 1H), 5.38 (s, 2H), 3.52 (t, J= 6.4 Hz, 2H), 3.08 (t, J= 7.6 Hz, 2H), 1.74 (q, J= 7.6 Hz, 2H), 1.49 (t, J= 7.2 Hz, 2H), 1.23-1.45 (m, 17H); MS. m/z 442.3, [M+Na]+. 4-(ll-hydroxyundecyl)quinolin-8-ol (Kl) YD: 84%. l¥i NMR (400 MHz, ί/4-MeOD) 5 8.63 (d, J= 4.4 Hz, 1H), 7.51 (d,J = 8.4 Hz, 1H), 7.40 (t,J= 8.0 Hz, 1H), 7.28 (d, J = 4.0 Hz, 1H), 7.06 (d, J= 7.6 Hz, 1H), 3.51 (t, J= 6.8 Hz, 2H), 3.02 (t,J= 8.0 Hz, 2H), 1.71 (t,J= 7.6 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.12-1.31 (br, 15H); MS. m/z 316.2, [M+H]+. 4-(12-hydroxydodecyl)quinolin-8-ol (K2) YD: 86%. lYi NMR (400 MHz, CDCb) 58.52 (d, J= 4.4 Hz, 1H), 7.36 (dd, J= 8.4, 0.8 Hz, 1H), 7.31 (d, J= 7.6 Hz, 1H), 7.13 (d, J = 4.4 Hz, 1H), 6.99 (dd, J= 7.6, 1.2 Hz, 1H), 3.43 (t, J= 6.8 Hz, 2H), 2.89 (t, J= 7.6 Hz, 2H), 1.61 (quin, J= 7.6 Hz, 2H), 1.40 (quin, J= 6.8 Hz, 2H), 1.12 1.31 (br, 17H); MS. m/z 352.2, [M+Na]+.
Example 8 Preparation of (8-trifluoromethoxyquinol-2-yl)alkyl alcohols.
Method: The intermediate was synthesized through ring closure from 2-trifluoromethoxyaniline reacted with crotonaldehyde. Intermediate was reacted with corresponding Br(CH2)n-iOH (as illustrated above) to synthesize series compounds L. 9-(8-(trifhioromethoxy)quinolin-2-yl)nonan-l-ol (LI) YD: 41%. 'HNMR (400 MHz, CDCb) 58.06 (dd, J= 8.4, 1.2 Hz, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 7.6 Hz, 1H), 7.43 (d, J= 8.0 Hz, 1H), 7.34 (dd, J= 8.4, 1.2 Hz, 1H), 3.61 (t, J= 6.4 Hz, 2H), 3.01 (t, J= 6.4 Hz, 2H), 1.81-1.85 (br, 2H), 1.53-1.56 (br, 2H), 1.21-1.35 (m, 15H); MS. m/z 355.9, [M+H]+. ll-(8-(trifhioromethoxy)quinolin-2-yl)undecan-l-ol (L2) YD: 41%. 'HNMR (400 MHz, ί/4-MeOD) 58.26 (t, J= 8.0 Hz, 1H), 7.86 (d, J= 7.6 Hz, 1H), 7.64 (t, J= 7.2 Hz, 1H), 7.47-7.56 (m, 2H), 3.51 (t, J= 6.8 Hz, 2H), 2.99 (t, J= 6.4 Hz, 2H), 1.79 (quin, J= 6.8 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.21-1.35 (m, 15H); MS. m/z 406.2, [M+Na]+. 14- (8-(trifluoromethoxy)quinolin-2-yl)tetradecan-l-ol (L3) YD: 37%. l¥i NMR (400 MHz, ί/4-MeOD) 5 8.27 (d, J= 8.4 Hz, 1H), 7.87 (d, J= 8.0 Hz, 1H), 7.65 (t, J= 7.2 Hz, 1H), 7.49-7.56 (m, 2H), 3.52 (t, J= 6.8 Hz, 2H), 3.01 (t, J= 7.6 Hz, 2H), 1.82 (quin, J= 7.2 Hz, 2H), 1.51 (quin, J= 6.8 Hz, 2H), 1.27-1.37 (m, 21H); MS. m/z 448.2, [M+Na]+. 15- (8-(trifluoromethoxy)quinolin-2-yl)pentadecan-l-ol (L4) YD: 32%. l¥i NMR (400 MHz, J4-MeOD+CDCb) 58.21 (d, J= 8.4 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.51 (d, J= 8.0 Hz, 1H), 7.46 (t,J= 8.4 Hz, 1H), 3.52 (t, J = 6.8 Hz, 2H), 2.99 (t,J= 7.6 Hz, 2H), 1.80 (quin, J= 7.6 Hz, 2H), 1.50 (quin, J= 7.2 Hz, 2H), 1.15-1.41 (br, 23H); MS. m/z 462.2, [M+Na]+.
Example 9 - Preparation of 2-N-substitutedalcohol-8-hydroxyquinoline
Reagents and conditions: (a) SeCb, dioxane, 50 to 80 °C; (b) N-methylpropagylamine or 2-(piperazin-l-yl) ethanol or NH2(CH2)n-1 OH, NaBH(OAc)3, 1,2-dichloroethane, rt.
Method: A solution of 8-hydroxy-2-methylquinoline (6.0 g, 37.7 mmol) in dioxane (15 ml) was added to a stirred solution of Se02 (6.3 g, 56.8 mmol) in dioxane (80 ml) dropwise at 50 °C and the mixture was heated up to 80 °C for further 20 h. The resulting mixture was filtered. The filtrate was concentrated and the residue purified by column chromatography with Hex/EA = (15:1 to 10:1) to give 8-hydroxyquinoline-2-carboxaldehyde (2.45g, 38 %) derivatives as intermediates. Intermediate was converted into A'-substi luted compounds by reductive amination with aminoalcohol, aminoalkyne or other heterocycles to give series of compounds. 8-alkoxy-2-methyl quinoline were oxidized to give 8-alkoxyquinoline-2- carboxaldehyde derivatives and followed by the same method to give compounds M to O. 2-((4-(2-hydroxyethyl)piperazin-l-yl)methyl)quinolin-8-ol (Ml) YD: 76%. l¥i NMR (400 MHz, CDCb) 58.02 (d, J= 8.4 Hz, 1H), 7.43 (d, J= 8.4 Hz, 1H), 7.34 (t, J= 8.0 Hz, 1H), 7.22 (d, J= 7.6 Hz, 1H), 7.10 (d, J= 6.8 Hz, 1H), 3.73 (s, 2H), 3.61 (t, J = 6.8 Hz, 2H), 2.51 (t, J= 5.6 Hz, 10H); HRMS (ESI): Calcd for [M+Na]+: 310.1526, Found: 310.1527. 2-(4-((5-chloro-8-methoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol (M2) YD: 76%. Ή NMR (400 MHz, CDCb) 58.23 (d, J= 8.8 Hz, 1H), 7.59 (d, J= 8.8 Hz, 1H), 7.21 (d, J= 8.4 Hz, 1H), 6.68 (d, J= 8.8 Hz, 1H), 3.81 (s, 3H), 3.72 (s, 2H), 3.44 (t, J= 4.8 Hz, 2H), 2.35-2.38 (m, 10H); MS. m/z 336.1, [M+H]+. 2-(4-((5-chloro-8-ethoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol (M3) YD: 53%. NMR (400 MHz, CDCb) 58.36 (d, J= 8.8 Hz, 1H), 7.68 (d, J= 8.4 Hz, 1H), 7.34 (d, J= 8.4 Hz, 1H), 6.83 (d, J= 8.4 Hz, 1H), 4.18 (q, J= 6.8 Hz, 3H), 3.84 (s, 2H), 3.54 (t, J = 5.2 Hz, 2H), 2.45-2.50 (br, 10H), 1.49 (t, J= 6.8 Hz, 3H); MS. m/z 350.1, [M+H]+. 2-(4-((5-chloro-8-isopropoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol (M4) YD: 61%. Ή NMR (400 MHz, ί/4-MeOD) 58.52 (d, J= 8.8 Hz, 1H), 7.81 (d, J= 8.8 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.14 (d, J= 8.4 Hz, 1H), 4.87 (m, 1H), 3.89 (s, 2H), 3.67 (t, J= 6.0 Hz, 2H), 2.54-2.62 (br, 10H), 1.45 (t, J= 6.0 Hz, 6H); MS. m/z 364.1, [M+H]+. 2-(4-((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)piperazin-l-yl)ethane (M5) YD: 76%. l¥i NMR (400 MHz, ί/4-MeOD) 58.40 (d, J= 8.4 Hz, 1H), 7.71 (d, J= 8.8 Hz, 1H), 7.42 (d, J= 8.4 Hz, 1H), 6.99 (d, J= 8.4 Hz, 1H), 3.97 (d, J= 6.8 Hz, 2H), 3.84 (s, 2H), 3.65 (t, J= 6.0 Hz, 2H), 3.44 (t, J= 4.8 Hz, 2H), 2.56 (br, 8H), 2.51 (t, J= 4.8 Hz, 2H), 1.37-1.43 (m, 1H), 0.62-0.66 (m, 2H), 0.37-0.40 (m, 2H); MS. m/z 376.2, [M+H]+. 2-(4-((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol (M6) YD: 39%. 'HNMR (400 MHz, ί/4-MeOD) δ 8.53 (d, J= 8.8 Hz, 1H), 7.80 (d, J= 8.8 Hz, 1H), 7.70 (s, 1H), 4.11 (s, 3H), 3.89 (s, 2H), 3.67 (t, J= 6.0 Hz, 2H), 2.63 (br, 8H), 2.55 (t, J= 6.0 Hz, 2H), 1.93 (s, 1H); MS. m/z 370.1, [M+H]+. 2-(4-((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)piperazin-l-yl)ethanol (M7) YD: 82%. 'HNMR (400 MHz, CDCb) 58.43 (d, J= 8.8 Hz, 1H), 7.71 (d, J= 8.8 Hz, 1H), 7.58 (s, 1H), 4.22 (d, J= 12 Hz, 2H), 3.88 (s, 2H) 3.61 (t, J= 6.4 Hz, 2H), 2.56 (t, J= 5.2 Hz, 10H), 1.41-1.44 (m? in), 0.57-0.62 (m, 2H), 0.33-0.37 (m, 2H); MS. m/z 410.1, [M+Na]+. 2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol (Nl) YD: 49%. l¥i NMR (400 MHz, CDCb) 58.08 (d, J= 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 7.40 (t, J= 8.0 Hz, 1H), 7.28 (d, J= 8.0 Hz, 1H), 7.15 (d, J= 7.6 Hz, 1H), 3.90 (s, 2H), 3.41 (d, J = 2.0 Hz, 2H), 2.39 (s, 3H), 2.31 (d, J= 2.0 Hz, 1H); MS. m/z 249.1, [M+H]+. 5-chloro-2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol (N2) YD: 38%. 'HNMR (400 MHz, CDCb) 58.47 (d, J= 8.4 Hz, 1H), 7.71 (d, J= 8.8 Hz, 1H), 7.47 (d, J= 8.0 Hz, 1H), 7.08 (d, J= 8.4 Hz, 1H), 3.93 (s, 2H), 3.42 (d, J= 2.0 Hz, 2H), 2.40 (s, 3H), 2.31 (t, J= 2.0 Hz, 1H); MS. m/z 261.0, [M+H]+. N-((5-chloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N3) YD: 52%. l¥i NMR (400 MHz, CDCb) 58.48 (d, J= 8.8 Hz, 1H), 7.80 (d, J= 8.8 Hz, 1H), 7.46 (d, J= 8.4 Hz, 1H), 6.93 (d, J= 8.4 Hz, 1H), 4.05 (s, 3H), 4.00 (s, 2H), 3.42 (d, J= 2.0 Hz, 2H), 2.37 (s, 3H), 2.27 (t, J= 2.0 Hz, 1H), MS. m/z 297.0, [M+Na]+. N-((5-chloro-8-ethoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N4) YD: 64%. lYi NMR (400 MHz, CDCb) 58.48 (d, J= 8.8 Hz, 1H), 7.79 (d, J= 8.8 Hz, 1H), 7.46 (d, J= 8.8 Hz, 1H), 6.96 (d, J= 8.4 Hz, 1H), 4.32 (t, J= 6.8 Hz, 2H), 4.01 (s, 2H), 3.45 (d, J = 2.0 Hz, 2H), 2.41 (s, 3H), 2.28 (t, J= 2.0 Hz, 1H), 1.59 (t, J= 6.8 Hz, 3H); MS. m/z 289.1, [M+H]+. N-((5-chloro-8-isopropoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N5) YD: 76%. lYi NMR (400 MHz, CDCb) 58.47 (d, J= 8.8 Hz, 1H), 7.73 (d, J= 8.8 Hz, 1H), 7.46 (d, J= 8.0 Hz, 1H), 7.03 (d, J= 8.4 Hz, 1H), 4.80 (m, 1H), 3.99 (s, 2H), 3.44 (d, J= 2.4 Hz, 2H), 2.41 (s, 3H), 2.28 (t, J= 2.4 Hz, 1H), 1.48 (d, J= 6.4 Hz, 6H); MS. m/z 303.1, [M+H]+. N-((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N6) YD: 58%. l¥i NMR (400 MHz, CDCb) 58.48 (d, J= 8.4 Hz, 1H), 7.77 (d, J= 8.8 Hz, 1H), 7.45 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 8.4 Hz, 1H), 4.09 (d, J= 12 Hz, 2H), 4.01 (s, 2H), 3.45 (d, J = 2.0 Hz, 2H), 2.41 (s, 3H), 2.28 (t, J= 2.0 Hz, 1H), 1.42 ~ 1.50 (m, 1H), 0.65-0.70 (m, 2H), 0.420.45 (m, 2H); MS. m/z 337.1, [M+Na]+. N-((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N7) YD: 58%. ln NMR (400 MHz, CDC13) 58.47 (d, J= 8.8 Hz, 1H), 7.74 (d, J= 8.8 Hz, 1H), 7.60 (s, 1H), 4.20 (s, 3H), 3.99 (s, 2H), 3.43 (d, J= 2.0 Hz, 2H), 2.41 (s, 3H), 2.29 (t, J= 2.0 Hz, 1H); MS. m/z 309.0, [M+H]+. N-((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine (N8) YD: 76%. Ή NMR (400 MHz, CDCI3) 58.45 (d, J= 8.8 Hz, 1H), 7.71 (d, J= 8.8 Hz, 1H), 7.59 (s, 1H), 4.25 (d, J= 7.6 Hz, 2H), 3.95 (s, 2H), 3.40 (d, J= 2.0 Hz, 2H), 2.40 (s, 3H), 2.28 (t, J = 2.0 Hz, 1H), 1.41-1.45 (m, 1H), 0.57-0.62 (m, 2H), 0.36 (dd, J = 10.0, 4.8 Hz, 2H); MS. m/z 371.0, [M+Na]+. 8-((5-chloro-8-methoxyquinolin-2-yl)methylamino)octan-l-ol (Ol) YD: 44%. l¥i NMR (400 MHz, ί/4-MeOD) 58.55 (d, J= 8.8 Hz, 1H), 7.69 (d, J= 8.8 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 7.16 (d, J= 8.4 Hz, 1H), 4.07 (s, 5H), 3.50 (t, J= 6.8 Hz, 2H), 2.63 (t, J = 7.2 Hz, 2H), 1.56 (quin, J= 7.2 Hz, 2H), 1.50 (quin, J= 6.8 Hz, 2H), 1.29-1.32 (br, 10H); MS. m/z 351.2, [M+H]+. 8-((5-chloro-8-ethoxyquinolin-2-yl)methylamino)octan-l-ol (02) YD: 41%. l¥i NMR (400 MHz, ί/4-MeOD) 58.51 (d, J= 8.8 Hz, 1H), 7.66 (d, J= 8.4 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.12 (d, J= 8.4 Hz, 1H), 4.29 (q, J= 6.8 Hz, 2H), 4.07 (s, 2H), 3.51 (t, J= 6.8 Hz, 2H), 2.64 (t, J= 7.2 Hz, 2H), 1.47-1.58 (m, 7H), 1.31 (br, 9H); MS. m/z 365.2, [M+H]+. 8-((5-chloro-8-isopropoxyquinolin-2-yl)methylamino)octan-l-ol (03) YD: 31%. Ή NMR (400 MHz, ί/4-MeOD) 58.55 (d, J= 8.8 Hz, 1H), 7.66 (d, J= 8.8 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.19 (d, J= 8.4 Hz, 1H), 4.89 (m, 1H), 4.15 (s, 2H), 3.52 (t, J= 6.4 Hz, 2H), 2.71 (t, J= 12 Hz, 2H), 1.59 (quin, J= 6.8 Hz, 2H) 1.46-1.50 (m, 8H), 1.33 (br, 9H); MS. m/z 379.2, [M+H]+ .8-((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-l-ol (04) YD: 29%. l¥i NMR (400 MHz, ί/4-MeOD) 58.54 (d, J= 8.4 Hz, 1H), 7.67 (d, J= 8.8 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H), 7.15 (d, J= 8.4 Hz, 1H), 4.09 (s + d, J= 6.8 Hz, 4H), 3.51 (t, J= 6.8 Hz, 2H), 2.67 (t, J= 12 Hz, 2H), 1.59 (quin, J= 12 Hz, 2H), 1.43-1.51 (m, 3H), 1.29-1.42 (br, 10H), 0.66-0.89 (m, 2H), 0.44 (dd, J= 10.4, 4.8 Hz, 2H); MS. m/z 391.2, [M+H]+. 8-((5,7-dichloro-8-methoxyquinolin-2-yl)methylamino)octan-l-ol (05) YD: 37%. Ή NMR (400 MHz, ί/4-MeOD) 58.54 (d, J= 8.8 Hz, 1H), 7.71 (s, 1H), 7.65 (d, J = 8.8 Hz, 1H), 4.14 (s, 3H), 4.12 (s, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.70 (t, J= 12 Hz, 2H), 1.60 (quin, J= 6.8 Hz, 2H), 1.50 (m, 2H), 1.33 (br, 9H); MS. m/z 385.1, [M+H]+. 8-((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-l-ol (06) YD: 56%. 'HNMR (400 MHz, ί/4-MeOD) 58.51 (d, J= 8.4 Hz, 1H), 7.69 (s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 4.22 (d, J= 12 Hz, 2H), 4.10 (s, 2H), 3.52 (t, J= 6.8 Hz, 2H), 2.68 (t, J= 12 Hz, 2H), 1.59 (quin, J= 12 Hz, 2H), 1.51 (quin, J= 6.8 Hz, 2H), 1.28-1.42 (br, 11H), 0.55-0.60 (m, 2H), 0.30-0.33 (m, 2H); MS. m/z 425.2, [M+H]+. 6-(bis((8-methoxyquinolin-2-yl)methyl)amino)hexan-l-ol (PI) 'HNMR (400 MHz, (74-MeOD) 58.18 (d, J= 8.4 Hz, 2H), 7.80 (d, J= 8.4 Hz, 2H), 7.44 (t, J = 8.0 Hz, 2H), 7.38 (d, J= 8.0 Hz, 2H), 7.13 (d, J= 12 Hz, 2H), 4.02 (s, 6H), 3.99 (s, 4H), 3.40 (t, J= 6.8 Hz, 2H), 2.59 (t, J= 6.8 Hz, 2H), 1.56 (quin, J= 6.8 Hz, 2H), 1.41 (quin, J= 6.8 Hz, 2H), 1.27 (quin, J= 7.6 Hz, 2H), 1.18 (quin, J= 6.8 Hz, 2H); MS. m/z 482.3, [M+Na]+. FIG. 1A shows C12 inhibited Αβ aggregation in the presence or absence of zinc ions using a microscopy analysis after Congo red staining. FIG.IB and FIG.2 show that C12 dissolved preformed Αβ aggregates. FIGs. 3A-B show that compounds Cl2, CQ and C12 intermediate protected neuron cells from zinc-induced ίΑβ. Only compound C12 was effective toward zinc-free aggregates (FIG. 3B). FIG. 4 shows induction of neurite outgrowth triggered by compounds B3, C3, and D3, respectively, on undifferentiated PC 12 cells. FIG. 5 shows quinoline derivatives increased expression of GAP43. FIG. 6 shows compound C12 and B3 improved performance of learning in fAβ-induced memory-deficit mice. C12 and B3 (10 mg/kg) increased riding time of fAβ-lesioned mice in a rotarod test. FIGs. 7A-D show compound C12 improved learning of memory-deficit fAβ-lesioned mice in the Morris water maze test. Mice were assessed for the total duration of movement (FIG. 7A) and total duration of distance (FIG. 7B) to climb onto the hidden platform; and also quantified the appearance to target zone (FIG. 7C) indicating the relative time (compared to total time in swimming) to entry into a zone around the hidden platform; and for average swimming velocity (FIG. 7D) to discriminate enhanced memory from enhanced motor activity. FIG. 8 shows an increase in GAP43 level and decrease in ίΑβ level in memory-deficit fAβ-lesioned mice by compound Cl2.
The foregoing description of the exemplary embodiments of the invention has been presented only for the purposes of illustration and description and is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many modifications and variations are possible in light of the above teaching.
The embodiments and examples were chosen and described in order to explain the principles of the invention and their practical application so as to enable others skilled in the art to utilize the invention and various embodiments and with various modifications as are suited to the particular use contemplated. Alternative embodiments will become apparent to those skilled in the art to which the present invention pertains without departing from its spirit and scope.
Accordingly, the scope of the present invention is defined by the appended claims rather than the foregoing description and the exemplary embodiments described therein.
Some references, which may include patents, patent applications and various publications, are cited and discussed in the description of this invention. The citation and/or discussion of such references is provided merely to clarify the description of the present invention and is not an admission that any such reference is “prior art” to the invention described herein. All references cited and discussed in this specification are incorporated herein by reference in their entireties and to the same extent as if each reference was individually incorporated by reference.
In this specification where reference has been made to external documents, or other sources of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.
Claims (17)
- CLAIMS What is claimed is:1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof:Formula (I) (I) wherein: R1 is hydrogen, (Ci-Cs)alkyl, (Ci-C8)alkylene(C3-Cs)cycloalkyl, (Ci-Cs)haloalkyl, or (Ci-Cs)alkylene(C6-C2o)aryl; R2 is hydrogen or halogen; R3 is hydrogen, halogen, (Ci-Cs)alkyl, or (Ci-Cs)alkoxy; R4 is hydrogen, halogen, (Ci-Cs)alkyl, (Ci-Cs)alkoxy, or (Ci-Cs)haloalkyl; R5 is hydrogen or (Ci-C2o)alkanol; R6 is hydrogen; and R7 is (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-Cs)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-Cs)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-C8)alkylene(8-methoxyquinolin-2-yl); or (II) wherein: R1, R2, R3, R4 and R6 are each as defined in (I) above; R5 is (C5-C2o)alkanol; and R7 is hydrogen, (C6-C2o)alkanol, CH2(N(CH2CH2)2N)CH2CH2OH, (Cio-Ci3)alkyleneOCOCH3, (Ci-C8)alkylene(Ci-C6)alkylamino(Ci-C6)alkynyl, (Ci-Cs)alkyleneamino(C3-C2o)alkanol, or (Ci-C8)alkyleneamino(Ci-C2o)alkanol(Ci-Cs)alkylene(8-methoxyquinolin-2-yl).
- 2. The compound of claim 1, (A) wherein: R1 is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH2)2, CH2CH(CH3)2, CF3, or benzyl; R2 is hydrogen, F, or Cl; R3 is hydrogen, F, Cl, CH3, or OCH3; R4 is hydrogen, F, Cl, Br, CH3, OCH3, or CF3; R5 is hydrogen, (CFh)iiOFl, or (CH2)i20H; R6 is hydrogen; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i30H, (CH2)i4OH, (CH2)i5OH, (CH2)ioOCOCH3, (CH2)iiOCOCH3, (CH2)i20C0CH3, (CH2)i30C0CH3, CH2(N(CH2CH2)2N)CH2CH2OH, CH2N(CH3)CH2C^CH, CH2NH(CH2)80H, or CH2N((CH2)60H)CH2(8-methoxyquinolin-2-yl); or (B) wherein: R1, R2, R3, R4 and R6 are each as defined in (A) above; R5 is (CH2)nOH, or (CH2)i20H; and R7 is hydrogen, (CH2)9OH, (CH2)ioOH, (CH2)nOH, (CH2)i20H, (CH2)i30H, (CH2)i40H, (CH2)i5OH, (CH2)ioOCOCH3, (CH2)iiOCOCH3, (CH2)i20C0CH3, (CH2)i30C0CH3, CH2(N(CH2CH2)2N)CH2CH2OH, CH2N(CH3)CH2C^CH, CH2NH(CH2)80H, or CH2N((CH2)60H)CH2(8-methoxyquinolin-2-yl).
- 3. The compound of claim 2, wherein R1 is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH2CH(CH2)2, CF3, or benzyl; R2, R3, R4, R5, and R6 are each independently hydrogen; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i30H, (CH2)i40H, (CH2)i50H, CH2(N(CH2CH2)2N)CH2CH2OH, or CH2N(CH3)CH2C=CH.
- 4. The compound of claim 2, wherein R1 is hydrogen, CH3, CH2CH3, CH2CH(CH3)2, CH2CH(CH2)2, or CH(CH3)2; R2, R3, R5, and R6 are each independently hydrogen; R4 is CH3, F, Cl, Br, CF3, or OCH3; and R7 is (CH2)9OH, (CH2)ioOH, (CH2)hOH, (CH2)i20H, (CH2)i30H, (CH2)i5OH, (CH2)ioOCOCH3, (CH2)iiOCOCH3, (CH2)i20C0CH3, (CH2)i30C0CH3, CH2NH(CH2)80H, CH2(N(CH2CH2)2N)CH2CH2OH, or CH2N(CH3)CH2 C^CH.
- 5. The compound of claim 2, wherein R1 is hydrogen, CH3, CH2CH3, CH(CH2)2, or CH2CH(CH2)2; R2,R4 are each independently Cl; R3, R5, and R6 are each independently hydrogen; and R7 is (CH2)nOH, CH2NH(CH2)80H, or CH2N(CH3)CH2C=CH.
- 6. The compound of claim 2, wherein R1 is hydrogen, CH3, CH2CH3, CH2CH(CH3)2, CH2CH(CH2)2, CH(CH3)2, or benzyl; R2, R3, R4, R6, and R7 are each independently hydrogen; and R5 is (CH2)nOH or (CH2)i20H.
- 7. The compound of claim 2, wherein R1 is CH3; R2, R5, and R6 are each independently hydrogen; R3 and R4 are each independently OCH3 or Cl; and R7 is (CH2)nOH.
- 8. The compound of claim 2, which is selected from the group consisting of: 9- (8-(benzyloxy)quinolin-2-yl)nonan-1 -ol, 10- (8-(benzyloxy)quinolin-2-yl)decan-1 -ol, 11 -(8-(benzyloxy)quinolin-2-yl)undecan-1 -ol, 12- (8-(benzyloxy)quinolin-2-yl)dodecan-l-ol, 13- (8-(benzyloxy)quinolin-2-yl)tridecan-l-ol, 14- ((8-(benzyloxy)quinolin-2-yl)tetradecan-l-ol, 15- (8-(benzyloxy)quinolin-2-yl)pentadecan-l-ol, I l-(8-(benzyloxy)-5-methylquinolin-2-yl)undecan-l-ol, II -(8-(benzyloxy)-6-methylquinolin-2-yl)undecan-1 -ol, 11 -(8-(benzyloxy)-5-fluoroquinolin-2-yl)undecan-1 -ol, 11 -(8-(benzyloxy)-5-chloroquinolin-2-yl)undecan-1 -ol, 2-(9-hydroxynonyl)quinolin-8-ol, 2-(10-hydroxydecyl)quinolin-8-ol, 2-(1 l-hydroxyundecyl)quinolin-8-ol, 2-(12-hydroxydodecyl)quinolin-8-ol, 2-(13-hydroxytridecyl)quinolin-8-ol, 2-(14-hydroxytetradecyl)quinolin-8-ol, 2-(15-hydroxypentadecyl)quinolin-8-ol, 2-(1 l-hydroxyundecyl)-5-methylquinolin-8-ol, 2-(11 -hydroxyundecyl)-6-methylquinolin-8-ol, 5-chloro-2-(l l-hydroxyundecyl)quinolin-8-ol, 9- (8-methoxyquinolin-2-yl)nonan-1 -ol, 10- (8-methoxyquinolin-2-yl)decan-1 -ol, 11 -(8-methoxyquinolin-2-yl)undecan-1 -ol, 12- (8-methoxyquinolin-2-yl)dodecan-l-ol, 13- (8-methoxyquinolin-2-yl)tridecan-l-ol, 14- ((8-methoxyquinolin-2-yl)tetradecan-1 -ol, 15- (8-methoxyquinolin-2-yl)pentadecan-l-ol, I l-(8-methoxy-5-methyl quinolin-2-yl)undecan-l-ol, II -(5-fluoro-8-methoxyquinolin-2-yl)undecan-1 -ol, 12-(5-fluoro-8-methoxyquinolin-2-yl)dodecan-l-ol, 9-(5-chloro-8-methoxyquinolin-2-yl)nonan-1 -ol, 1 l-(5-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, 15-(5-chloro-8-methoxyquinolin-2-yl)pentadecan-1 -ol, I l-(5-bromo-8-methoxyquinolin-2-yl)undecan-l-ol, II -(8-methoxy-5 -(trifluoromethyl)quinolin-2-yl)undecan-1 -ol, I l-(5,8-dimethoxyquinolin-2-yl)undecan-l-ol, II -(8-methoxy-6-methylquinolin-2-yl)undecan-1 -ol, 11 -(6-fluoro-8-methoxyquinolin-2-yl)undecan-1 -ol, 11 -(6-chloro-8-methoxyquinolin-2-yl)undecan-1 -ol, 11 -(7-fluoro-8-methoxyquinolin-2-yl)undecan-1 -ol, I l-(7-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, II -(5-chloro-6,8-dimethoxyquinolin-2-yl)undecan-1 -ol, 11 -(6-chloro-5,8-dimethoxyquinolin-2-yl)undecan-1 -ol, 11 -(5,7-dichloro-8-methoxyquinolin-2-yl)undecan-1 -ol, 9- (8-ethoxyquinolin-2-yl)nonan-1 -ol, 10- (8-ethoxyquinolin-2-yl)decan-1 -ol, 11 -(8-ethoxy quinolin-2-yl)undecan-1 -ol, 12- (8-ethoxyquinolin-2-yl)dodecan-l-ol, 13- (8-ethoxy quinolin-2-yl)tridecan-l-ol, 14- ((8-ethoxyquinolin-2-yl)tetradecan-l-ol, 15- (8-ethoxyquinolin-2-yl)pentadecan-l-ol, I l-(8-ethoxy-5-methyl quinolin-2-yl)undecan-l-ol, II -(8-ethoxy-5-fluoroquinolin-2-yl)undecan-1 -ol, 9-(5-chloro-8-ethoxyquinolin-2-yl)nonan-1 -ol, 1 l-(5-chloro-8-ethoxyquinolin-2-yl)undecan-l-ol, 15-(5-chloro-8-ethoxyquinolin-2-yl)pentadecan-l-ol, I l-(5-bromo-8-ethoxyquinolin-2-yl)undecan-l-ol, II -(5,7-dichloro-8-ethoxyquinolin-2-yl)undecan-1 -ol, 9- (8-isopropoxyquinolin-2-yl)nonan-1 -ol, 10- (8-isopropoxyquinolin-2-yl)decan-1 -ol, 11 -(8-isopropoxyquinolin-2-yl)undecan-1 -ol, 12-(8-isopropoxyquinolin-2-yl)dodecan-l-ol, 13- (8-isopropoxyquinolin-2-yl)tridecan-l-ol, 14- ((8-isopropoxyquinolin-2-yl)tetradecan-1 -ol, 15- (8-isopropoxyquinolin-2-yl)pentadecan-l-ol, 11 -(8-isopropoxy-5-methyl quinolin-2-yl)undecan-1 -ol, 11 -(5-fluoro-8-isopropoxyquinolin-2-yl)undecan-1 -ol, 9-(5-chloro-8-isopropoxyquinolin-2-yl)nonan-1 -ol, 11 -(5-chloro-8-isopropoxyquinolin-2-yl)undecan-1 -ol, 15-(5-chloro-8-isopropoxyquinolin-2-yl)pentadecan-1 -ol, I l-(5-bromo-8-isopropoxyquinolin-2-yl)undecan-l-ol, II -(5,7-dichloro-8-isopropoxyquinolin-2-yl)undecan-1 -ol, 9- (8-(cyclopropylmethoxy)quinolin-2-yl)nonan-1 -ol, 10- (8-(cyclopropylmethoxy)quinolin-2-yl)decan-1 -ol, 11 -(8-(cyclopropylmethoxy)quinolin-2-yl)undecan-1 -ol, 12- (8-(cyclopropylmethoxy)quinolin-2-yl)dodecan-1 -ol, 13- (8-(cyclopropylmethoxy)quinolin-2-yl)tridecan-1 -ol, 14- ((8-(cyclopropylmethoxy)quinolin-2-yl)tetradecan-1 -ol, 15- (8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-1 -ol, 1 l-(8-(cyclopropylmethoxy)-5-methylquinolin-2-yl)undecan-l-ol, I l-(8-(cyclopropylmethoxy)-5-fluoroquinolin-2-yl)undecan-l-ol, 9- (5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)nonan-l-ol, II -(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-1 -ol, 15-(5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)pentadecan-1 -ol, 11 -(5-bromo-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-1 -ol, 1 l-(5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)undecan-l-ol, 5,7-dichloro-2-(l l-hydroxyundecyl)quinolin-8-ol, 10- (5-chloro-8-methoxyquinolin-2-yl)decan-l-ol, acetic acid 10-(5-chloro-8-methoxyquinolin-2-yl)decyl ester, I l-(5-chloro-8-methoxyquinolin-2-yl)undecan-l-ol, acetic acid 1 l-(5-chloro-8-methoxyquinolin-2-yl)undecyl ester, 12- (5-chloro-8-methoxyquinolin-2-yl)dodecan-l-ol, acetic acid 12-(5-chloro-8-methoxyquinolin-2-yl)dodecyl ester, 13- (5-chloro-8-methoxyquinolin-2-yl)tridecan-l-ol, acetic acid 13-(5-chloro-8-methoxyquinolin-2-yl)tridecyl ester, II -(8-methoxyquinolin-4-(-yl)undecan-1 -ol, 11 -(8-ethoxy quinolin-4-(-yl)undecan-1 -ol, 11 -(8-isopropoxyquinolin-4-(-yl)undecan-1 -ol, 11 -(8-(cyclopropylmethoxy)quinolin-4-(-yl)undecan-1 -ol, 11 -(8-(benzyloxy)quinolin-4-(-yl)undecan-1 -ol, 12-(8-(benzyloxy)quinolin-4-(-yl)dodecan-1 -ol, 4-(( 11 -hydroxyundecyl)quinolin-8-ol, 4- (( 12-hydroxydodecyl)quinolin-8-ol, 9-(8-(trifluoromethoxy)quinolin-2-yl)nonan-1 -ol, 11 -(8-(trifluoromethoxy)quinolin-2-yl)undecan-1 -ol, 14- ((8-(trifluoromethoxy)quinolin-2-yl)tetradecan-1 -ol, 15- (8-(trifluoromethoxy)quinolin-2-yl)pentadecan-1 -ol, 2-((4-((2-hydroxyethyl)piperazin-1 -yl)methyl)quinolin-8-ol, 2-(4-(((5-chloro-8-methoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5-chloro-8-ethoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5-chloro-8-isopropoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-(4-(((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)piperazin-l-yl)ethanol, 2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol, 5- chloro-2-((methyl(prop-2-ynyl)amino)methyl)quinolin-8-ol, N((5-chloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5-chloro-8-ethoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5-chloro-8-isopropoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5,7-dichloro-8-methoxyquinolin-2-yl)methyl)-N-methylprop-2-yn-l-amine, N((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methyl)-N-methylprop-2-yn-l- amine, 8-((5-chloro-8-methoxyquinolin-2-yl)methylamino)octan-l-ol, 8-((5-chloro-8-ethoxyquinolin-2-yl)methylamino)octan-l-ol, 8-((5-chloro-8-isopropoxyquinolin-2-yl)methylamino)octan-l-ol, 8-((5-chloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-l-ol, 8-((5,7-dichloro-8-methoxyquinolin-2-yl)methylamino)octan-l-ol, 8-((5,7-dichloro-8-(cyclopropylmethoxy)quinolin-2-yl)methylamino)octan-1 -ol, and 6- (bis((8-methoxyquinolin-2-yl)methyl)amino)hexan-1 -ol.
- 9. The compound of claim 1, wherein R2 is hydrogen.
- 10. The compound of claim 1, wherein R1 is hydrogen, (Ci-Cs)alkyl, (Ci-Cs)alkylene(C3-C8)cycloalkyl, or (Ci-Cs)haloalkyl.
- 11. A composition comprising a therapeutically effective amount of a compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 12. A method for the treatment of Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury, comprising administering to a subject in need thereof a therapeutically effective amount of a composition as claimed in claim 11.
- 13. A compound as claimed in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, when used in treating Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury.
- 14. Use of a compound as claimed in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer’s disease, brain traumatic injury, and/or spinal cord injury.
- 15. A method for improving learning and/or memory performance in a patient of Alzheimer's disease, comprising administering a therapeutically effective amount of composition as claimed in claim 11 to the patient with Alzheimer's disease.
- 16. A compound as claimed in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, when used in improving learning and/or memory performance in a patient with Alzheimer’s disease.
- 17. Use of a compound as claimed in any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for improving learning and/or memory performance in a patient with Alzheimer’s disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/034960 WO2014163622A1 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013385618A1 AU2013385618A1 (en) | 2015-09-24 |
AU2013385618B2 true AU2013385618B2 (en) | 2017-01-05 |
Family
ID=51658752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013385618A Ceased AU2013385618B2 (en) | 2013-04-02 | 2013-04-02 | Multifunctional quinoline derivatives as anti-neurodegenerative agents |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2981525A4 (en) |
JP (1) | JP6153179B2 (en) |
KR (1) | KR101802048B1 (en) |
CN (1) | CN105452224B (en) |
AU (1) | AU2013385618B2 (en) |
BR (1) | BR112015024472A2 (en) |
IL (1) | IL241295A0 (en) |
RU (1) | RU2642466C2 (en) |
WO (1) | WO2014163622A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101725326B1 (en) * | 2015-04-23 | 2017-04-12 | 대한민국 | A novel isolated midroorganism having antibiotic activity and a production method of pseudane using the same |
CN105949120B (en) * | 2016-05-27 | 2018-07-24 | 广东工业大学 | A kind of application of four teeth chelating type list quinoline and preparation method thereof and metal ion control agent as neurodegenerative disease |
KR102281647B1 (en) * | 2020-12-09 | 2021-07-30 | 메디케어제약 주식회사 | Method of producing a derivative-piperazine |
CN113527200B (en) * | 2021-05-27 | 2022-12-02 | 北京斯利安药业有限公司 | Preparation method of cloquinadol |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682927A (en) * | 1968-06-15 | 1972-08-08 | Massimo Carissimi | 5,7-bichloro-8-hydroxy-2-acetylamino quinoline |
WO1994010164A1 (en) * | 1992-10-27 | 1994-05-11 | Janssen Pharmaceutica N.V. | 4-quinolinyl derivatives with anti-helicobacter activity |
US6127360A (en) * | 1997-07-07 | 2000-10-03 | Kowa Co., Ltd. | Diamine derivatives and pharmaceutical containing the same |
WO2004007461A1 (en) * | 2002-07-16 | 2004-01-22 | Prana Biotechnology Limited | 8-hydroxy quinoline derivatives |
WO2004076386A2 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
US20050165052A1 (en) * | 2001-01-17 | 2005-07-28 | Mohamed Fakhfakh | Substituted quinolines for the treatment of protozoa and retrovirus co-infections |
WO2011150156A2 (en) * | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
CN102526052A (en) * | 2012-01-19 | 2012-07-04 | 华南师范大学 | Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
HUP9903906A3 (en) * | 1996-08-13 | 2001-01-29 | Gerolymatos P N Sa | Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
JP4455064B2 (en) | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | Quinoline derivatives and their use as 5-HT6 ligands |
JP2005536462A (en) | 2002-04-30 | 2005-12-02 | ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド | Quinoline derivative as caspase-3 inhibitor, process for producing the same and pharmaceutical composition containing the same |
GB0322510D0 (en) | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
WO2005035534A1 (en) * | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same |
US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
FR2889525A1 (en) * | 2005-08-04 | 2007-02-09 | Palumed Sa | NOVEL POLYQUINOLINE DERIVATIVES AND THEIR THERAPEUTIC USE. |
AU2007280984A1 (en) * | 2006-07-25 | 2008-02-07 | Envivo Pharmaceutical Inc. | Quinoline derivatives |
US8729097B2 (en) * | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
-
2013
- 2013-04-02 RU RU2015137621A patent/RU2642466C2/en not_active IP Right Cessation
- 2013-04-02 JP JP2016506301A patent/JP6153179B2/en not_active Expired - Fee Related
- 2013-04-02 BR BR112015024472A patent/BR112015024472A2/en not_active IP Right Cessation
- 2013-04-02 EP EP13881032.0A patent/EP2981525A4/en not_active Withdrawn
- 2013-04-02 KR KR1020157026392A patent/KR101802048B1/en active IP Right Grant
- 2013-04-02 AU AU2013385618A patent/AU2013385618B2/en not_active Ceased
- 2013-04-02 WO PCT/US2013/034960 patent/WO2014163622A1/en active Application Filing
- 2013-04-02 CN CN201380075030.2A patent/CN105452224B/en not_active Expired - Fee Related
-
2015
- 2015-09-08 IL IL241295A patent/IL241295A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3682927A (en) * | 1968-06-15 | 1972-08-08 | Massimo Carissimi | 5,7-bichloro-8-hydroxy-2-acetylamino quinoline |
WO1994010164A1 (en) * | 1992-10-27 | 1994-05-11 | Janssen Pharmaceutica N.V. | 4-quinolinyl derivatives with anti-helicobacter activity |
US6127360A (en) * | 1997-07-07 | 2000-10-03 | Kowa Co., Ltd. | Diamine derivatives and pharmaceutical containing the same |
US20050165052A1 (en) * | 2001-01-17 | 2005-07-28 | Mohamed Fakhfakh | Substituted quinolines for the treatment of protozoa and retrovirus co-infections |
WO2004007461A1 (en) * | 2002-07-16 | 2004-01-22 | Prana Biotechnology Limited | 8-hydroxy quinoline derivatives |
WO2004076386A2 (en) * | 2003-02-25 | 2004-09-10 | Topotarget Uk Limited | Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors |
WO2011150156A2 (en) * | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
CN102526052A (en) * | 2012-01-19 | 2012-07-04 | 华南师范大学 | Application of 2-gylcosyl chinoline compound in preparing acetylcholine esterase resisting medicines |
Non-Patent Citations (19)
Title |
---|
CAS Registry Number 1065599-09-8; STN Entry Date 24 October 2008 * |
CAS Registry Number 1069623-04-6; STN Entry Date 02 November 2008 * |
CAS Registry Number 1069767-88-9; STN Entry Date 02 November 2008 * |
CAS Registry Number 1069927-53-2; STN Entry Date 03 November 2008 * |
CAS Registry Number 1070248-65-5; STN Entry Date 03 November 2008 * |
CAS Registry Number 1111784-97-4; STN Entry Date 25 February 2009 * |
CAS Registry Number 1212904-49-8; STN Entry Date 22 March 2010 * |
CAS Registry Number 1212979-09-3; STN Entry Date 22 March 2010 * |
CAS Registry Number 1213553-49-1; STN Entry Date 23 March 2010 * |
CAS Registry Number 1213861-92-7; STN Entry Date 24 March 2010 * |
CAS Registry Number 1309289-38-0; STN Entry Date 13 June 2011 * |
CAS Registry Number 1380715-47-8; STN Entry Date 03 July 2012 * |
CAS Registry Number 1394435-94-9; STN Entry Date 18 September 2012 * |
CAS Registry Number 1422555-72-3; STN Entry Date 07 March 2013 * |
CAS Registry Number 341021-63-4; STN Entry Date 14 June 2001 * |
CAS Registry Number 747346-14-1; STN Entry Date 17 September 2004 * |
CAS Registry Number 802874-31-3; STN Entry Date 27 December 2004 * |
CHIA E. W. et al.,Bioorganic & Medicinal Chemistry, 2008, Vol. 16, pages 9432-9442 * |
KONDO, M. et al., "Solution-phase Assembly of a Rhodium Complex via Specific Hydrogen Bonding between Barbituric Acid and Triaminopyrimidine Moieties", Chemistry Letters, 2010, vol. 39, no. 11, pages 1166-1167 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014163622A1 (en) | 2014-10-09 |
EP2981525A1 (en) | 2016-02-10 |
JP2016515617A (en) | 2016-05-30 |
CN105452224A (en) | 2016-03-30 |
BR112015024472A2 (en) | 2017-07-18 |
JP6153179B2 (en) | 2017-06-28 |
KR20150136070A (en) | 2015-12-04 |
EP2981525A4 (en) | 2016-12-21 |
CN105452224B (en) | 2017-12-26 |
KR101802048B1 (en) | 2017-12-28 |
RU2642466C2 (en) | 2018-01-25 |
WO2014163622A8 (en) | 2014-11-13 |
AU2013385618A1 (en) | 2015-09-24 |
RU2015137621A (en) | 2017-05-11 |
IL241295A0 (en) | 2015-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2013385618B2 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
US9155739B2 (en) | Histone deacetylases (HDACs) inhibitors | |
CA2672212A1 (en) | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | |
Ghandi et al. | Unique substituted 3-oxo-1, 2, 3, 4-tetrahydropyrazino [1, 2-a] benzimidazole-1-carboxamides generated by Ugi 3CC using bifunctional starting material | |
JP2017206511A (en) | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | |
US9302992B2 (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
Khlebnicova et al. | Betulinic acid-azaprostanoid hybrids: Synthesis and pharmacological evaluation as anti-inflammatory agents | |
US10654862B2 (en) | Methods for the chemical synthesis of pyrrole-linked bivalent compounds, and compositions thereof | |
ES2726807T3 (en) | Compositions, synthesis and methods of use of 1- [1-phenyl-cyclobutyl] isobutylamine derivatives | |
CN111393500A (en) | Oleanolic acid derivative with conjugated diene structure C ring and preparation method and application thereof | |
TWI543969B (en) | Multifunctional quinoline derivatives as anti-neurodegenerative agents | |
Sari et al. | Synthesis and characterization of unsaturated diacyl and alkyl-acyl piperazine derivatives | |
Wolan et al. | A convenient titanium-mediated intermolecular alkyne–carbonate coupling reaction | |
RU2541545C2 (en) | Method of obtaining hydrochlorides of adamantane amines | |
RU2642924C1 (en) | Method of producing 5-phenyl-3- (trifluoromethyl) -1n-pyrazole-4-amine | |
Ignatovich et al. | Synthesis of functionalized amides of 2-(arylamino) pyrimidine series. | |
Heindel et al. | Alcoholysis of 4-chloroquinolines to 4 (1H)-quinolones | |
SU1705286A1 (en) | Method of 3-alkylsubstituted 4-hydroxyquinoline-2-ones synthesis | |
JPS58109455A (en) | N-benzyl amino acid derivative and its preparation | |
Kochikyan et al. | Synthesis of new carboxy lactones and some their transformations | |
WO1992006980A1 (en) | Compounds having n-methyltryptamine tricyclic structure for the therapy of degenerative encephalopathies | |
JP2011074073A (en) | Method for production of 2-(1-benzothiophen-5-yl) ethanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |